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Infection with Human Immunodeficiency Virus (HIV), the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS), remains one of the most significant healthcare challenges 
facing South Africa. The development of alternative therapeutic strategies targeting different 
stages of the viral life cycle remains an important ongoing biomedical research objective. 
Recently, a monoclonal antibody which binds CD4, the primary cellular host receptor of HIV, has 
shown outstanding antiviral efficacy in Phase II clinical trials. However, the high costs associated 
with conventional therapeutic monoclonal antibody production, which involves expression, 
assembly and secretion of full-length antibodies using large-volume mammalian cell cultures; 
limit the clinical use of such compounds in the South African public healthcare setting. 
Accordingly, this study investigated the feasibility of generating a functional Ibalizumab Fab 
(IBLZFab) fragment using an E. coli-based expression system. Heavy and Light Variable (VH/VL) 
Ibalizumab chains were expressed in BL21 E. coli and functional Fab fragments were 
reconstituted by oxidative refolding in the bacterial periplasm. The success of reconstitution and 
efficacy of the Fab fragment was assessed in vitro by analytical SDS-PAGE, Surface Plasmon 
Resonance (SPR) and cell culture models of HIV infection. The calculated CD4-binding affinity (KD) 
of IBLZFab was 11.3 nM, which compares favorably with the (KD) values of most antibody-antigen 
interactions, which are typically in the low nanomolar (nM) range. Viral inhibition studies were 
also performed to evaluate whether the Fab fragment had any detectable neutralization activity. 
Even though neutralization activity was obtained at a high concentration the bacterially 
expressed IBLZFab fragment was able to inhibit CAP210 viral entry, illustrating the feasibility of 
expressing and purifying functional Ibalizimab Fab fragments using a bacterial expression system. 
Ongoing efforts are focused on improving yields of purified IBLZFab through optimization of the 
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1 Chapter 1: Introduction 
The Human Immunodeficiency Virus (HIV), the causative agent of Acquired immunodeficiency 
Syndrome (AIDS), remains one of the most significant public healthcare challenges facing South 
Africa, with approximately 6.4 million individuals infected (12.2 % prevalence) [1]. According to 
the World Health Organization there were approximately 36.9 million people living with HIV at 
the end of 2014 with 2 million newly infected patients [2]. Sub-Saharan Africa accounted for 70 
% (25.8 million) of new infections globally. To date 34 million people have died from HIV-related 
causes globally and no effective vaccine or eradicative cure is currently available [1]. 
 
AIDS was first described as a disease in 1981 by the Centers for Disease Control (CDC) of the 
United States [3, 4]. The initial description of the high risk sexual behavior group included patients 
receiving blood transfusions, intravenous drug users and homosexual or bisexual males [3].   
 
1.1 HIV life cycle 
 
HIV is a slow replicating retrovirus, belonging to the Retroviridae family that arose from several 
zoonotic transmissions of the simian immunodeficiency viruses over the past century [5]. HIV-1 
infects CD4 T-helper cells, macrophages and dendritic cells thereby disrupting both the adaptive 
and innate immune responses [6]. Viral replication occurs through a series of steps that are 
initiated when the envelope glycoprotein spikes on the virus effectively engage the host cell 
surface receptor, CD4 and the co-receptor CC-chemokine receptor 5 (CCR5) or chemokine (C-X-C 
motif) receptor 4 (CXCR4) [7]. This attachment allows fusion of the viral membrane to the host 
cellular membrane and entry of the virus particle into the cell. Once inside the cell, the viral capsid 
protein partially uncoats, allowing for reverse transcription of the viral RNA genome, and the viral 
RNA genome then allows formation of the pre-integration complex (PIC) [8].  
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The PIC complex is then imported into the nucleus where PIC-associated integrase supported by 
host chromatin-binding protein lens epithelium-derived growth factor (LEDGF) coordinates the 
formation of the integrated provirus [9]. Host RNA polymerase II mediates transcription of the 
integrated provirus, and the mRNA strands are then exported from the nucleus by host protein 
factors, where the structural proteins are produced [9]. Assembly of virus-like particles takes 
place at the plasma-membrane. Once complete, ESCRT (endosomal sorting complex required for 
transport) complexes mediate viral-particle budding and release from the cell [10]. The last step 
of the viral life-cycle is maturation which occurs subsequent to budding. Protease-mediated 
maturation through proteolysis of precursor proteins turns the nascent virus particles into 
infectious virions [11]. 
 
Each step in the viral life-cycle presents an opportunity for the development of new drug targets. 
Since binding and entry into the host cell play a fundamental role in viral tropism and infection 
efficiency [7], exploiting our understanding of HIV entry may likely provide targets for novel drug 
treatments.   
 
1.2 HIV entry into host CD4-positive cells 
 
HIV entry is a multistep process that involves the binding of virions to the target cell, primarily 
via surface expressed CD4 receptors [7] (Figure 1). CD4 receptor binding occurs through the 
gp120 protein of the viral envelope. The envelope protein is a heavily glycosylated trimer 
comprised of gp120 and gp41 heterodimers [12] .The initial association between gp120 and the 
host cell is non-specific electrostatic interactions between the positively charged domains on 
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Figure 1. Outline of HIV entry: 
To gain access to CD4 T-helper cells, macrophages and/or dendritic cells, the HIV envelope (Env), made up of gp120 and gp41 subunits (1), attaches 
to the cell surface receptor CD4 (2). The subsequent conformational change in Env allows co-receptor binding (3) and the beginning of the fusion 
process by the formation of the fusion peptide and the six-helix bundle (4).   (Adapted from [7]).  
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Binding of viral gp120 to CD4 results in the rearrangement of the variable regions of gp120 (V1, 
V2 and V3) (Figure 1). This causes the formation of a bridging sheet which is made up of two 
double-stranded β sheets that are spatially separated in the unliganded state [14]. The 
conformational changes in gp120 allows the bridging sheet together with the extended V3 loop 
to interact with the co-receptor of choice, either CCR5 or CXCR4 [14]. CD4 projects further from 
the cell surface than chemokine receptors and therefore CD4 is required to bend after 
engagement with gp120 in order for the complex to be associated with the co-receptor [15]. 
Attachment of gp120 to the co-receptor is followed by fusion of the viral and host cell 
membranes [7]. This process involves the formation of a gp41 complex that results in a six-helix 
bundle (6HB, Figure 1) which leads to the development of a fusion pore and entry of viral contents 
into the cell [7]. The exposure of the hydrophobic gp41 fusion peptide is triggered by co-receptor 
binding [16]. The fusion peptide pierces the host cell membrane and allows heptad repeats from 
each gp41 subunit in the trimer to fold at the hinge region bringing an amino-terminal helical 
region (HR-N) and a carboxy-terminal helical region (HR-C) together; bringing the viral membrane 
and the host membrane into close proximity via the 6HB [7]. This rearrangement initiates the 
formation of the fusion pore and the eventual entrance of the viral capsid into the host cell [15, 
16] (Figure 1). 
 
Once inside the host cell, viral RNA is converted into double stranded DNA before being 
integrated into the host genome by viral reverse transcriptase and integrase, respectively. The 
viral DNA serves as a template for the transcription of novel RNA genomes, which are packaged 
into mature, infectious viruses that bud off at the cell surface [1].  
 
1.3 Current HIV treatment regimens 
 
There are four major drug classes for the treatment of HIV: entry inhibitors, reverse transcriptase 
inhibitors, integrase inhibitors and protease inhibitors. Highly active antiretroviral therapy 
(HAART) is the combination of two or more classes of drugs for the synergistic control of HIV 
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infection [14]. Existing antiretroviral therapy (ART) has dramatically reduced the morbidity and 
mortality associated with HIV/AIDS, but therapy is still associated with high costs, toxic side-
effects and, most importantly, the emergence of drug-resistant viral strains. Thus, the 
development of alternative therapeutic strategies targeting different stages of the viral life cycle 
remains an important ongoing research objective. 
 
Entry inhibitors have become increasingly popular candidate antiviral compounds due to their 
activity against multi-drug resistant viruses [17]. One advantage of targeting HIV entry is the 
extracellular site of action which is easily accessible and does not require intracellular transport 
of drug compounds such as RT or protease inhibitors. There are currently two entry inhibitors 
approved for the treatment of HIV-infected patients; the CCR5 antagonist  Maraviroc and the 
fusion inhibitor Enfuvirtide [15].  
 
Enfuvirtide, a fusion inhibitor, was the first entry inhibitor approved for treatment of HIV-1 
infection in 2003 [15]. Enfuvirtide is a 36 amino acid long synthetic peptide based on the HR2 
sequence of gp41. The HR2 region plays a crucial role in the formation of the 6HB during 
membrane fusion by interacting with HR1 [18]. This peptide disrupts the formation of the 6HB by 
competing with HR2 of gp41 for binding with HR1 [18, 19]. Maraviroc is a CCR5 antagonist, which 
is only effective against HIV strains that use CCR5 co-receptors during viral entry; as a 
consequence, it is recommended that patients undergo tropism testing before administering 
Maraviroc as part of the treatment regime [20]. There are, however, disadvantages to the use of 
entry inhibitors, such as the potential disruption of host receptor function (in the case of 
compounds that target host factors), while  the sequence and structural diversity of the Env 
protein frequently leads to differences in potency of antiviral entry inhibitors against different 
viral strains [21]. Despite this, entry inhibitors are of special interest as they target a pivotal step 
in the life-cycle of the virus.  
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1.4 Monoclonal Antibody (mAb) therapy 
 
Antibodies are host glycoproteins that make up one of the primary effectors of the adaptive 
immune response. They are produced by specialized B lymphocytes, known as plasma cells, in 
response to the presence of non-self or foreign molecules. Antibodies can directly inactivate 
antigens and indirectly lead to neutralization through enhanced phagocytosis elicited by 
macrophages, neutrophils, dendritic cells and/or natural killer (NK) cells [22]. Antigenic peptides 
derived from pathogens (viruses and bacteria) ingested by phagocytic cells are presented in 
association with Major Histocompatibility Complex (MHC) class II molecules to cognate T- and B-
lymphocytes which ultimately results in the clonal selection and proliferation of antigen-specific, 
antibody-secreting B-lymphocytes [23, 24]  
 
Once bound to the appropriate antigen the B lymphocytes differentiate, producing memory B 
cells as well as antibody secreting  plasma clones which generate antibodies that will recognize 
the identical antigenic epitope that associated with the antigen receptor [24]. The memory B cells 
produced during the immune response remain dormant until they are activated by their 
particular antigen, enhancing the antibody response when re-exposed to a specific antigen [24]. 
Monoclonal antibodies (mAbs) are produced by a single B lymphocyte clone which recognizes a 
specific antigenic epitope, whereas polyclonal antibodies are produced by a myriad of 
proliferating lymphocytes, recognizing numerous antigenic epitopes [24]. The electrophoretic 
mobility of antibodies usually places them in the γ-globulin fraction of serum. Antibodies, often 
referred to as immunoglobulins (Ig) are made up of four polypeptides or chains with a molecular 
weight of ~150 kDa in total [24]. Two identical copies of a heavy (∼55 kDa) and light (∼25 kDa) 
chain held together by disulfide and non-covalent bonds make a Y-shaped Ig [25]. The light chains 
can consist of one of the two types; lambda (l) and kappa (k). The variable (V) regions of both the 
heavy and light chains cover approximately the first 110 amino acids of each chain, forming the 
antigen-binding (Fab) regions, while the remaining sequences are constant (C) regions, forming 
the Fc (fragment crystallizable) regions for effector ligand recognition and binding (Figure 2) [24]. 
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In mammals, there are five classes of Ig; IgG, IgM, IgA, IgD, and IgE, these classes differ in 
antigenicity, size, function and charge [24].  
 
IgG antibodies can be further categorized into subclasses; IgG1, IgG2, IgG3 and IgG4 with IgG1 
being the most abundant antibody present in the human body [26]. IgG antibodies share 90 % 
similarity in amino acid levels but each subclass responds to different types of antigens [27]. The 
IgG1 antibody response is stimulated primarily by soluble protein antigens and membrane 
proteins [28]. Bacterial capsular polysaccharide antigens trigger IgG2 antibody responses [28] 
and IgG3 can be attributed to being a pro-inflammatory antibody [27]. IgG4 antibody responses 
can be triggered by allergens and are often expressed following repeated, long term exposure to 
antigens in a non-infectious situation such as individuals allergic to bees or long-term bee keepers 
that underwent immune therapy [29, 30].  
 
Antibody diversity is a function of hyper-variable sequences within the variable domains known 
as the complementarity-determining regions (CDRs), which are responsible for antigen-binding 
specificities [31]. Both the variable regions of the light and heavy chains consist of 6 CDRs; known 
as CDR L1 to L6 and CDR H1 to H6 respectively [31]. The 6 CDR sequences in the variable domains 
of Ig molecules are believed to act synergistically to enable specific antigen recognition; CDR H3 
is thought to be the largest surface area of antigen recognition whereas the other CDRs are said 
to be involved in enhanced binding affinity to the antigen [32]. The genetic diversity of CDR1 and 
CDR2 are encoded by the germline and are further adapted by somatic mutation [31]. The CDRL3 











Figure 2. Structural schematic of an antibody: 
The Ig is made of two identical heavy (pink) and light (yellow) chains. The chains are linked by disulfide 
bonds and consist of constant (C) and variable (V) regions. The effector domain, Fc, forms the stem of the 
antibody while the antigen binding region, known as the Fab fragment, is found at the top of the antibody. 
The variable heavy (VH) and variable light (VL) chains are referred to as the Fv region. The Fab fragment 
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A genetically diverse antibody repertoire is the key component in humoral immunity and is vital 
to the development of a functional adaptive immune response [33]. The primary antibody 
repertoire is formed during early development through the re-arrangement of programmed gene 
segments mediated by the recombination activation gene (RAG) [33, 34]. Upon antigen 
recognition, diversification and maturation of the antibody response occurs giving rise to the 
secondary antibody repertoire [33, 34]. Recombination and somatic hypermutation are the two 
main mechanisms responsible for the diversity of the secondary antibody repertoire, primarily 
targeting regions within the complementarity-determining region (CDR) of the antibody [33]. 
Recombination involves the re-arrangement of the variable (V), diversity (D) and joining (J) genes 
of antibodies resulting in an almost limitless sequence diversity within the antibody repertoire 
[33, 35, 36]. 
 
In humans, somatic hypermutation is the primary mechanism of diversification of the secondary 
antibody repertoire in response to antigenic stimuli [33, 37]. Upon recognition of infecting 
particles, naïve B-cells undergo somatic hypermutation by mutating the V regions of the antibody 
genes [38]. These single base mutations usually have no effect on antigen recognition, some 
mutations even exhibit deleterious effects on either proper folding of the antibody protein or 
antigen recognition [33]. However, some mutations produced through somatic hypermutation 
result in enhanced affinity to pathogenic epitopes, consequently providing a platform for the 
positive selection of high affinity antibodies, characteristic of a mature immune response [39, 
40]. 
 
1.4.1 mAb derivatives 
 
Fab fragments, a derivative of mAbs comprising of the antigen binding region (Figure 2) are used 
in biopharmaceutical research and diagnostics and are particularly beneficial in the analysis of 
antigen-antibody interactions [41]. Fabs are conventionally produced through the enzymatic 
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digestion of a bivalent mAb by either papain or pepsin [42]. The digested Fab fragments are then 
purified from the digestion mix; a number of techniques may be employed such as affinity 
chromatography with either protein A or protein G, ion exchange chromatography, antigen 
affinity chromatography or size exclusion chromatography [41]. The other widely used approach 
to producing Fab fragments is transient expression of the light and heavy chain of the fragment 
in mammalian cell lines; the two peptides are required to assemble simultaneously and are joined 
by an inter-chain disulfide bond to comprise the Fab fragment [41].  
 
An antibody derivative apart from the Fab fragment that is clinically useful and commercially 
available is the single-chain Fv fragment (scFv) [43]. These scFv fragments are noncovalent 
peptides, of ~25-30 kDa, made up of the variable heavy and variable light chain of an antibody, 
stabilized by a hydrophilic flexible peptide linker between 10 to 12 residues long [43, 44]. 
  
1.4.2 Monoclonal antibodies used in biopharmaceutical applications and therapies 
 
Since their introduction into the market in 1986, bioprocessing technology for therapeutic mAb 
production has greatly advanced [45]. Due to the commercial success of mAbs, substantial 
investment in research and development by both industry and academia has been attracted [46]. 
The heightened interest in antibody therapy has resulted in the evolution of detailed mAb 
engineering techniques that have enabled successful application of  antibodies and fragments 
thereof in many therapeutic areas [46].  MAbs constitute the largest single class of biological 
drugs under development where mAbs secured 8 of the top 20 spots for best-selling 
biotechnology drugs in 2007 [47]. All protective antibodies that have been developed in response 
to vaccines inhibit or clear pathogenic infection, these antibodies are directed to constant or 
invariant molecular components on the pathogen [48].  
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1.4.2.1 mAb therapy used in the treatment of cancer  
 
This mAb therapy has also been applied to the treatment of cancer [49]. Human cancer cells 
express unique surface antigens, which represent a diverse spectrum of targets that are 
overexpressed, selectively expressed or mutated compared with normal cells [49]. Identifying 
suitable antigens for antibody-based therapeutics has been the main challenge and molecular 
techniques allowing the alteration of effector functions, pharmacokinetics, size and 
immunogenicity of the antibody have emerged as key elements in the development of mAb-
based therapies [49]. Oncological mAb therapies function through modulating the immune 
system by altering T cell activation for example, or through altering receptor or antigen function 
[50]. Tumor cell killing by mAbs involve several mechanisms, some of which include; induction of 
apoptosis by direct action of the mAb or immune-mediated cell killing mechanisms such as 
complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) 
[49]. The US- Food and Drug Administration (FDA) has approved approximately 12 antibodies for 
the treatment of various solid tumors and hematological malignancies [49]. Some of these 
include Trastuzumab, a humanized IgG1 mAb for the treatment of breast cancer, Bevacizumab, 
also a humanized IgG1 mAb used in first and second line treatment of metastatic colon cancer 




1.4.2.2 The market of mAbs targeting autoimmune conditions  
 
Since 2013 the sales and product approval of mAb products has significantly increased, with 
approximately four to five new mAb approvals each year [51]. The global sales revenue for 
therapeutic mAb products in 2013 was around $75 million which constitutes around fifty percent 
of the total sales of all biopharmaceutical products [51]. As of May 2016, 62 therapeutic mAbs 
have been approved by the FDA, some approved in 2015 include mAbs such as Nivolumab, a 
programmed death receptor-1 blocking antibody used in the treatment of severe plaque 
psoriasis, Deratumumab, a mAb that induces apoptosis in CD38 expressing tumour cells for the 
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treatment of multiple myeloma and Mepolizumab, an interleukin-5 antagonist used in the 
treatment of severe asthma [52]. MAbs used in the treatment of autoimmune disorders and 
cancer are the two largest focus areas and comprise almost 85 % of mAbs that are currently 
marketed [53]. There are approximately 20 commercially available mAbs used in cancer  therapy 
and 21 commercially available mAbs used in the treatment of autoimmune disorders, some of 
which include; Crohn’s disease, psoriasis, asthma, multiple sclerosis, rheumatoid arthritis and 
osteoporosis [53]. Autoimmune disorders and cancer still seem to be receiving the most 
development attention with 25 and 22 new mAbs in phase 3 clinical trials, respectively [53]. 
Monoclonal antibody products will continue to dominate as the major class of biopharmaceutical 
products as the rate of approved mAbs increases each year [51, 53].  
 
1.4.2.3 Antibodies used in HIV Vaccine therapy  
 
A vaccine that can be used to target HIV-1 would need to elicit antibodies that target a large 
number of fast evolving highly diverse viral strains, since the amino acid sequences of envelope 
spikes can differ by as much as >35 % [54]. Consequently, high affinity antibodies that are able to 
penetrate the glycan shield and bind effectively to highly diversified spikes are needed [48]. 
Among infected individuals 2 to 4 years post infection, approximately 10 – 30 % develops 
antibodies with the ability to neutralize a broad range of viral isolates [55]. Of this small fraction 
<1 % exhibit exceptional cross clade activity and are referred to as broadly neutralizing antibodies 
(bNAbs) [56].  
 
Until recently, characterizing and identifying mAbs was difficult due to the few techniques 
available at the time. Despite this, several bNAbs against HIV-1 were identified; while the first 
neutralizing antibodies (NAbs) identified were not very potent, they did provide insights into the 
regions of Env that were susceptible to antibody-mediated neutralization [48]. The four 
conserved sites include the CD4 binding site (CD4bs), the primary receptor for viral entry; the 
Asn160 glycan-dependent site associated with the hypervariable domain V1 and V2; the Asn332 
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glycan-dependent site at the base of the V3 loop and the membrane proximal external region 
(MPER) on gp41 [57] (refer to Figure 3).  
 
In recent times three additional bNAbs that target regions outside the four conserved domains 
have been described, these include PGT151, 35O22 and 8ANC195 [58-60]. The epitope of the 
newly described PGT151 mAb comprises of residues and glycans at the interface of gp41 and 
gp120 and binding of this mAb is dependent on a properly formed, cleaved Env trimer [61]. 
35O22 is a potent HIV-mAb that binds a conserved region which spans across gp120 and gp41, 
the binding specificity of 35O22 represents a novel site of vulnerability on HIV-1 Env commonly 
stimulated by natural infection [58]. 8ANC195 was the first anti HIV bNAb that bound to an 
epitope spanning both the gp120 and gp41 subunits [59]. The neutralizing epitope comprises of 
N-linked glycans adjacent to the CD4bs on gp120 and regions on the gp41 subunit [59]. Another 
group of researchers have also elaborated on an epitope for the previously described, related 
antibodies 3BC176 and 3BC315, making this epitope distinct from the four well-established target 
sites [62]. Analysis of the bNAbs indicate that the target site is at the gp41-gp41 inter-subunit 
interface of the Env trimer in the pre-fusion conformation [62]. This epitope partially overlaps 











Figure 3.Broadly neutralizing antibodies that target the HIV Env spikes: 
An Electron microscopy image of HIV-1 Env trimer with antibody epitopes highlighted on the surface of 
the structure. There are 4 main epitopes highlighted; the CD4 binding site epitope (red), MPER binding 
site (yellow), V3 loop/Asn332 binding site (blue) and V1/V2 loop/Asn160 binding site (green). In recent 
times 3 newly discovered bNAbs outside the 4 conserved domains have been described, the target site is 








HIV bNAbs   
PGT151; 35O22; 8ANC195 
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Despite being a well-protected, buried region on the HIV Env spike that is highly conserved, the 
CD4bs is accessible to both CD4 receptors and CD4bs antibodies (Figure 3) [48, 64]. Of those that 
target the CD4bs, NIH45-46 and 3BNC117 are the most potent antibodies [48, 65]. Structural 
analysis of the antibodies reveal that even though they were isolated from different individuals, 
antibodies derived from the variable heavy chain (VH)-gene segment VH1-2 share a common 
mode of antigen recognition whereby framework residues contribute to CD4 mimicry [48, 66, 67] 
[64, 68]. CD4 bNAbs are able to bind to the CD4bs when a short complementarity-determining 
region 3 of the light chain (CDR L3) interacts with the gp120 V5 and the gp120 diversity (D) loops, 
as a short CDR L1 avoids clashes with glycans at Asn276 on the D loop [64, 66-68]. This mechanism 
allows these anti-CD4bs antibodies to compete for binding at the CD4bs on the viral gp120 Env, 
thereby inhibiting cell entry [48].  
 
Despite the myriad of anti-HIV therapies that have been described and implemented as part of a 
treatment regimen, without a bona fide cure the need to develop and discover new and improved 
approaches to combatting HIV is still an important, continuing research objective. One such agent 
that is being explored is the anti-CD4 monoclonal antibody, Ibalizumab. 
 
1.5 The anti-CD4 monoclonal antibody: Ibalizumab 
 
Ibalizumab (previously known as Hu5A8 and TNX-355) is a humanized IgG4 anti-CD4 mAb that 
mediates potent anti-HIV activity [69]. CD4 is a 55 kDa host cell surface glycoprotein composed 
of four immunoglobin-like domains (D1-D4) expressed on a subset of T lymphocytes, it also 
consists of a membrane spanning domain and a cytoplasmic tail which interacts with src-like 
tyrosine kinase [70, 71]. The amino acid sequence of D1 shares similarities with that of variable 
regions of immunoglobulins [72]. CD4 utilizes MHC class II molecules as a restriction element for 
antigen recognition and functions to enhance T-cell receptor (TCR)-mediated signaling [70]. MHC 
class II molecules are vital for the initiation of the antigen-specific immune response, as their 
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main function is to present processed antigens, primarily derived from exogenous sources such 
as bacterial or viral particles, to CD4+ T-lymphocytes [70]. CD4 associates directly with MHC II 
molecules, on antigen-presenting cells, which triggers the recruitment of a tyrosine kinase, p56lck 
on the CD4+ T-lymphocytes. This interaction mediates the activation of helper T cells thereby 
moderating the adaptive immune response [73]. Therefore, disruption of MHC antigen 
presentation directly affects immune responses to infection. 
 
Ibalizumab was generated by immunization of BALB/c mice with CD4+ CHO cell transfectants 
which were stably expressing full length human CD4 [69]. The anti-CD4 mAbs that were 
generated during this study were tested for their ability to cross-inhibit other anti-CD4 mAbs 
allowing the identification of mAbs that recognize spatially proximal or distinct epitopes on CD4 
[69]. Ibalizumab was distinguished by its failure to compete with neither the two D1-specific 
mAbs, Leu 3A and OKT4a nor with OKT4, the D3/D4-specific mAb [69]. The data obtained in this 
study suggested that Ibalizumab recognized a distinct epitope on CD4 from those defined by 
several other D1- and D3/D4-specific mAbs [69].  
 
Ibalizumab binds to the interface between domain 1 and 2 of CD4, away from the binding site of 
MHC class II molecules [74] (Figure 4). Moreover, all conformational changes induced by 
Ibalizumab appear to be localized, primarily making contact with the BC loop at the junction of 
D1 and D2 of CD4 located on the opposite end of the MHC II and gp120 binding sites [75]. There 
are minor, local conformational changes that occur at the binding interface of CD4 and 
Ibalizumab, these slight changes do not extend to other regions of CD4 likely explaining why this 
antibody does not interfere with CD4 receptor function [75, 76]. The anti-CD4 mAb inhibits CD4-
dependent virus entry and is able to inhibit a broad range of HIV isolates including R5, X4 and 
R5X4 strains. 
 




Figure 4. Three-dimensional structure of a complex of 2dCD4, the Fab fragment of Ibalizumab, gp120 
and the Fab fragment of 17b (obtained through structural alignment of the Ibalizumab Fab fragment 
and gp120 associated with 2dCD4) 
Side view of the Fab fragment of Ibalizumab and 2dCD4 in complex with gp120 and the Fab fragment of 
17b. 2dCD4 is in light green and magenta, the heavy chain of Ibalizumab in blue and the light chain in 
magenta. gp120 is in yellow, the heavy chain of 17b in salmon and the light chain in grey. The BC loop in 
D2 of CD4, constituting the core epitope of Ibalizumab are indicated. The diagram illustrates the distinct 
epitopes of Ibalizumab and gp120 to 2dCD4. The two binding sites of gp120 and Ibalizumab do not cause 
any steric hindrance to each other. gp120 binding is not affected by Ibalizumab binding to CD4 nor are 
any gp120-induced epitopes masked by this mAb.  Diagram rendered using PyMOL (PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC) and pdb files 1G9M and 3O2D.  
 
Phase II clinical trials have shown that Ibalizumab is well tolerated at therapeutic doses that 
achieve significant and sustained reductions in viral loads in treatment experienced HIV positive 
individuals failing standard therapy [17, 77, 78]. There were three main studies conducted on 
Ibalizumab which illustrate reductions in plasma HIV-1 RNA levels by > 1 log10 copies/ml in HIV 
infected patients [17, 77, 78] (Table 1). 
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Table 1. Summary of reduction in viral loads as observed in Ibalizumab clinical trials 
Study Dose (mg/kg) Reduction in Viral RNA 
levels (copies/ml) 
1. Antiretroviral Activity of the Anti-
CD4 Monoclonal Antibody TNX-
355 in Patients Infected with HIV 
Type 1 [77] 
3.0 mg/kg, 





2. Safety, Pharmacokinetics, and 
Antiretroviral Activity of Multiple 
Doses of Ibalizumab (formerly 
TNX-355), an Anti-CD4 
Monoclonal Antibody, in Human 
Immunodeficiency Virus Type 1-
Infected Adults [17] 
Arm A – 10mg/kg (weekly for 
9 weeks) 
Arm B – 10mg/kg (initially), 
6mg/kg (after 2 weeks) 
Arm C – 25mg/kg (every 2 
weeks for 8 weeks) 
0.5 to 1.7 log10 
Complete coating in 
arm B was not achieved 
after two weeks 
3. Phase 2 efficacy and safety of the 
novel entry inhibitor, TNX-355, in 
combination with optimized 
background regimen (OBR). [79] 
10mg/kg (weekly for 8 
weeks),10mg/kg (every 2 
weeks), and 
15mg/kg (every 2 weeks) 
0.95 to 1.16 log10 
 
In contrast to other entry inhibitors that target gp120, the interaction between gp120 and CD4 is 
not inhibited by ibalizumab; alternatively this mAb acts as an antiviral agent by preventing the 
interaction of CD4-bound gp120 with its co-receptors (CCR5 and/or CXCR4), via a mechanism 
thought to involve impedance of required structural rearrangements in the receptor complex 
[69] (Figure 4). Other anti-CD4 antibodies that bind domain 1 of CD4 and inhibit gp120 
attachment, have been found to be immunosuppressive, as they inhibit the function of MHC II 
peptides, and are not suitable for the treatment of HIV infection [76].  Immunosuppression occurs 
through competitive binding with MHC class II molecules, and adversely affects CD4-dependent 
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antigen presentation [80]. Conversely, Ibalizumab has shown no immunosuppressive effects in 
human trials, as it does not obstruct MHC II binding sites, and is an excellent candidate for anti-
viral therapy [76].  
 
Recently, bispecific antibodies (biNAb) were designed that combined the HIV inhibitory 
properties of Ibalizumab and gp120 specific bNAbs [81].  Two biNAbs that were created PG9-
Ibalizumab and PG16-Ibalizumab exhibited remarkable breadth and efficacy, and were able to 
neutralize 100 % of the 118 viruses tested at low picomolar concentrations. The mechanism 
behind the neutralization of this biNAb lies with the synergistic activity of both PG9 and 
Ibalizumab, an activity that is thought to be enhanced by the flexibility of the scFv fragment of 
PG9 on the biNAb molecule [81]. This study proposed that potent biNAbs such as the ones 
created should be considered as passive immunization agents against HIV-1. Thus far, these 
biNAbs are the only antibody-like molecules that are able to inhibit all viruses tested. 
Neutralization by PG9-Ibalizumab and PG16-Ibalizumab is more efficient than any other antibody 
described, including NIH45-46G54W [66, 81].  
 
While the broad-ranging therapeutic effects of Ibalizumab are impressive, the costs of sufficient 
antibody production hinder further development for clinical use. The reduced complexity and 
simple structure of Fab fragments compared to full antibodies allows for production in microbial 
cells, which is often attractive due to the rapid growth of prokaryotic expression systems [82]. 
The use of microbial expression vectors is cost effective and antibody derivatives show improved 
specificity along with therapeutic efficiency [82]. Antibody fragments exhibit superior tissue 
penetration compared to full antibodies and their reduced complexity allows the retention of 
specificity and affinity for their targets [82]. 
 
While there are well-documented challenges associated with the expression of functional Fab 
fragments in E. coli, largely related to chain folding and assembly, several of these types of 
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molecules have been produced successfully in bacterial expression systems and their clinical use 
is now well-established. Examples include ReoPro (abciximab), a platelet membrane glycoprotein 
IIb/IIIa receptor inhibitor used for the treatment of patients undergoing high-risk percutaneous 
coronary interventions, DigiFab, (digoxin immune Fab), used for the treatment of digoxin 
intoxication [83] and Crotiladae Polyvalent Immune Fab, (CroFab), a polyvalent bovine-derived 
antivenom [84]. Building on from this, this study investigated the feasibility of producing a 
functional Ibalizumab Fab fragment in E. coli, and evaluated the efficacy of this molecule as a 
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1.6 Aim and Objectives 
 
The overall aim of this study was to purify and reconstitute a functional Fab fragment of 
Ibalizumab following expression in E. coli. 
 
This was achieved by carrying out the following specific objectives:  
 
a. To design and synthesize codon-optimized sequences encoding the Heavy and Light 
chains of the Ibalizumab Fab region comprising variable (VH/VL) and constant (CH1/CL) 
domains; 
b. To clone these fragments into the prokaryotic pET15b expression vector; 
c. To optimize bicistronic expression of the heavy chain (VHCH1, henceforth designated 
IBLZH) and light chain (VLCL, henceforth designated IBLZL) sequences in BL21 Escherichia 
coli cells;  
d. To extract a functional Ibalizumab Fab fragment (IBLZFab) from the bacterial periplasm 
e. To purify IBLZFab by affinity chromatography procedures; 
f. To analyze the CD4-binding properties of IBLZFab by Surface Plasmon Resonance (SPR). 
g. To analyze the CD4-binding properties of IBLZFab by Enzyme-linked Immunosorbent 
Assays (ELISA) 
h. To analyze the neutralization properties of the IBLZFab by Neutralization assays using a 
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2 Chapter 2: Experimental procedures 
For expression of the Ibalizumab Fab regions, a bicistronic cassette was designed where both the 
light and heavy chain contained an OmpA (Outer-Membrane Protein A) leader sequence. The 
DNA encoding the variable and constant heavy chains, and the variable and constant light chains 
were separated by an inter-cistronic ribosomal binding site. 
 
Typically for IgG expression in mammalian cell lines, two different genes are transfected into a 
cell for stable expression, this can either be achieved by co-transfection of the genes or by 
designing a bicistronic expression vector [85]. However, the latter may be applied to Gram 
negative bacterial expression of antibody derivatives [86]. The inter-cistronic ribosomal binding 
site located between the heavy and light chains allows successful co-translation of the two 
cistrons on the same construct [87].  
 
2.1 Cloning of IBLZFab expression cassettes 
 
DNA cassettes encoding the heavy and light chains of the Ibalizumab Fab region were synthesized 
following codon optimization for expression in E. coli (GeneArt, Germany, Appendix 2). The 
cassettes contained 5ˈ- and 3ˈ-restriction endonuclease sequences (NcoI and XhoI respectively), 
an ompA signal sequence and encode an N-terminal 6x histidine tag to facilitate purification of 












Figure 5. Schematic representation of the bacterial IBLZ Fab (IBLZfab) expression cassette: 
The cassettes comprised of 5ˈ- and 3ˈ-restriction endonuclease sequences (BspHI and XhoI, respectively) 
for subcloning of the Fab fragment into pET15b; this includes the constant heavy chain 1, variable heavy 
chain, constant light chain and variable light chain in addition to the leader sequence OmpA required for 
periplasmic transport. The variable light and heavy chains were inserted as a complete construct together 
with the intercistronic ribosomal binding site (RBS).   
 
2.1.1 Preparation of IBLZFab-Encoding DNA for subcloning (Digestion and ligation of pET15b 
plasmid vector and IBLZFab Fragment) 
 
The pET15b vector DNA and the pMK-RQ plasmid containing the IBLZFab encoding DNA (GeneArt, 
Germany) was digested with the restriction endonucleases XhoI and NcoI (Fermentas; Canada) 
and BspHI and XhoI respectively. Restriction reactions contained XhoI (20 U), NcoI/BspHI (20 U), 
1 x Fast Digest buffer and either pET15b or pMK-RQ DNA (3 µg) and were incubated at 37˚C for 1 
hour. The resulting fragments were resolved on a 0.8 % agarose gel and the bicistronic IBLZFab-
encoding DNA was excised and purified using a MinElute Gel Extraction Kit (Qiagen; Germany), 
according to the maufacturer’s instructions. The concentration of the purified bicistronic IBLZFab 
DNA was measured spectrophotometrically at 260 nm (Nanodrop Technologies Inc; US) and used 
in ligation reactions. Ligation reactions were performed using a T4 DNA Ligase Kit (Fermentas; 
Canada). The reaction contained T4 DNA Ligase (1 U), 1 x T4 DNA Ligase buffer, pET15b vector 
DNA (50 ng) (Novagen, US) and IBLZFab insert DNA (50 ng). The reaction was incubated at 20˚C for 
4-6 hours. Competent DH5α E. coli were then transformed with 5µl of the ligation mix was then 
used to transform competent DH5α E. coli bacterial cells.  
 
6x histidine tag 
IBLZCL ompA IBLZVL IBLZCH1 IBLZHL 
RBS 
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Colonies visible on positive ligation agar plates were selected under sterile conditions and 
cultured in 10 ml Luria-Bertani (LB) broth containing ampicillin (100 µg/ml). Cultures were 
incubated at 37˚C overnight in an orbital shaker (250 rpm).  
 
Recombinant plasmids were isolated from overnight cultures using a Sigma GenElute™ Plasmid 
Miniprep Kit (Sigma-Aldrich; Germany), according to the manufacturer’s instructions. Screening 
for positive clones was performed by restriction mapping analysis. The pET15b-IBLZFab construct 
was linearized with XhoI and BamHI respectively (Fermentas; Canada), in order to obtain an 
estimation of the size of the plasmid containing the insert. A double digestion with XhoI and NcoI 
as well as XhoI and XbaI were performed to excise the IBLZFab-encoding DNA fragment from the 
recombinant pET15b vector. All digestion reactions were incubated at 37˚C for 1 hour. Digested 
products and controls (undigested and linearized plasmid including plasmid containing no insert) 
were resolved on a 1 % agarose gel and visualized in a Universal Hood Gel Doc instrument (Bio-
Rad; US) under UV light.  
 
In order to confirm the IBLZFab coding sequence in the pET15b-IBLZFab constructs Sanger 
sequencing was performed. T7 promoter and terminator primers were used during PCR reactions 
in order to amplify the IBLZFab sequence within the pET15b vector. Cycling conditions were as 
follows: an initial hotstart denaturation at 94˚C for 2 minutes was followed by 40 cycles with each 
cycle comprising denaturation at 94˚C for 1 minute, annealing at 50˚C for 30 seconds and 
elongation at 72˚C for 6 minutes. Once the cycles were complete, a final extension at 68˚C for 10 
minutes was applied. The reaction was cooled to 4˚C and maintained at this temperature until 
analyzed by agarose gel electrophoresis. Subsequent to gel analysis on a 1 % agarose gel the PCR 
reactions were purified using a GeneJet PCR Purification Kit (Thermo Fisher Scientific, US) as per 
the manufacturer’s instructions. A second cycling sequencing PCR reaction was performed which 
included fluorescent labeling of the DNA bases, allowing the sequence to be read. The PCR 
amplicon of the plasmid insert was sequenced using ABI cycle sequencing with an ABI 3730 DNA 
Analyzer. Sequences were viewed with the Sequencher™ v.5.1 software and the sequences were 
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compared with the DNA cassettes encoding the heavy and light chains of the Ibalizumab Fab 
region from GeneArt. 
 
2.2 Expression of the IBLZFab fragment in Bacterial Cell Culture 
 
Recombinant pET15-IBLZFab vectors were used to transform BL21 StarTM (DE3) E. coli (Thermo 
Fisher Scientific, US) under sterile conditions (see appendix for transformation procedure). 
Transformed E. coli cells were spread onto agar plates, containing ampicillin (100 µg/ml) and 
incubated at 37˚C overnight. A single colony was then selected and used to inoculate two 1 L 
Erlenmeyer flasks containing 250 ml of LB Broth supplemented with ampicillin (100 µg/ml). The 
cultures were incubated at 37˚C in an orbital shaker (250 rpm) overnight.  
 
The next day, 50 ml of overnight culture was added to 1 L of LB Broth supplemented with 
ampicillin (100 µg/ml). A total of 8 L of LB Broth was prepared and incubated at 37˚C in an orbital 
shaker (250 rpm) for approximately 5 hours or until the A600 reached 0.6 (mid log growth phase). 
The cultures were then incubated overnight at 30˚C in an orbital shaker (200 rpm) to induce over 
expression of the Fab fragment. 
 
2.3 Extraction and Purification of IBLZFab 
 
2.3.1 Extraction of protein expression 
 
Cultures expressing IBLZFab fragments were harvested by centrifugation (2000 x g for 20 minutes). 
The supernatant was discarded and the cell pellet washed with 1 x PBS Buffer (Phosphate 
Buffered Saline, pH 7.4, 30 ml/L of overnight expression culture pellet) to remove any excess LB 
broth. The washed cell pellet was harvested once more by centrifugation (2000 x g for 20 
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minutes). Each cell pellet obtained from 1 liter of LB broth was then treated with 250 ml of 
sucrose buffer (200mM tris(hydroxymethyl)aminomethane (Tris), 20 % sucrose and 1mM 
Ethylenediaminetetraacetic acid (EDTA), and 0.5 mg/ml of chicken lysozyme (Sigma-Aldrich; 
Germany) for 1 hour on ice with gentle agitation. One volume, 250 ml, of sterile distilled water 
was then added and the suspension agitated on ice for a further hour. The periplasmic fraction 
containing IBLZFab was recovered by centrifugation (10 000 x g, for 25 minutes).  
 
2.3.2 Purification procedure of IBLZFab 
 
Purification of the recombinant IBLZFab fragment was achieved by affinity chromatography using 
a kappa specific matrix (Capture Select Kappa Matrix (Life Technologies; US) which associated 
with the kappa light chain of IBLZFab.  
 
A total volume of 5 ml packed kappa specific agarose was added to the lysates (4 L) and incubated 
at 4˚C overnight with gentle stirring. The next morning the incubated beads were collected using 
an End fitting w/Fixed 10 µM Pyrex® Frit column (Sigma-Aldrich; Germany). The resin was then 
incubated with 15 ml of 20 mM Citric Acid and 1 M Sodium Chloride (pH 3.5) solution for one 
hour on ice with gentle stirring and thereafter collected. Samples (100 µl) were collected from 
the total cell sample, periplasmic fraction, unbound protein and elution for analysis by reducing 
and non-reducing SDS-PAGE (12.5 % gels) and western blot for the presence or absence of bands 
corresponding to IBLZFab using standard techniques [88]. 
 
For western blotting, proteins were transferred from SDS-PAGE gels onto Hybond-C 
nitrocellulose membrane (Bio-Rad; US) using a Trans-Blot SD Semi-Dry Transfer Cell System (Bio-
Rad; US) at 20 volts for 30 minutes. Thereafter, the membrane was blocked with 5 % fat free milk 
powder in Tris-buffered saline containing 0.1 % Tween-20 (T-TBS) for 1 hour at room temperature 
with gentle agitation. The membrane was then probed with a horseradish peroxidase (HRP)-
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conjugated monoclonal antibody to human Kappa light chain (Abcam®; UK) at a dilution of 1 in 
500 (details outlined in Appendix 1). The high background visible in western blot images could be 
attributed to a number of factors; high antibody concentration, the presence of excess SDS on 
the blot and even the exposure time of the antibody to the blot. Various concentrations were 
tested during western blot analysis and the concentration of 1 in 500 gave optimum detection. 
Detection of IBLZFab was performed by standard chemiluminescence methods and viewed using 
a Universal Hood Gel Doc instrument (Bio-Rad; US).  
 
The eluted protein was concentrated using an Amicon® Ultra-15 Centrifugal filter device 
(molecular weight cut off at 10 kDa) (Millipore; US), according to the manufacturer’s instructions 
(2 500 x g, for 12 minutes – repeated until 2 ml was obtained). The total protein concentration 
was determined using the BCA assay kit, (Thermo Fisher Scientific; US) (See Appendix 1 for 
procedure).  
 
This was then applied to a Sephadex G-75 AKTA-FPLC P-920 column (GE-Healthcare; UK) pre-
equilibrated with 1 x PBS, and separated at a flow rate of 1 ml/minute. Fraction volumes of 3 ml 
were collected and fractions within a single peak were and concentrated in an Amicon® Ultra-15 
Centrifugal filter device (Millipore; US) (molecular weight cut off at 10 kDa) before being 
electrophoretically separated using SDS-PAGE and Coomassie staining. A total of 30 l of sample 
was added to each well and all sample concentrations were normalized for analysis. Expression 
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2.4 Expression and Purification of 2 domain CD4 (2dCD4) 
 
Recombinant pET15-2dCD4 vectors (Novagen, US) (cloned in house), were used to transform 
BL21 StarTM (DE3) E. coli (Thermo Fisher Scientific, US) under sterile conditions [89]. The agar 
plates, containing ampicillin (100 µg/ml) were incubated at 37˚C overnight. A single colony was 
then selected and used to inoculate four 50 ml Falcon centrifuge tubes containing 20 ml of LB 
Broth and ampicillin (100 µg/ml). The cultures were incubated at 37˚C in an orbital shaker (250 
rpm) overnight.  
 
The next day, 20 ml of overnight culture was added to 1 L of LB broth supplemented with 
ampicillin (100 µg/ml). A total of 4 L of LB Broth was prepared and incubated at 37˚C in an orbital 
shaker (250 rpm) to induce log phase growth for approximately 5 hours or until the A600 reached 
0.6 (mid log growth phase). The cultures were then incubated overnight at 20˚C in an orbital 
shaker (200 rpm) to induce over expression of the 2dCD4 protein. 
 
2.4.1 Purification of 2dCD4 
 
The 6x histidine tagged 2dCD4 expressing E. coli was collected by centrifugation at 2 000 x g for 
20 minutes. The cell pellet collected from 1 L of expression media was re-suspended in 25 ml of 
PBS, pH 7.4 containing 0.5 mg/ml of chicken lysozyme (53,000 units/mg, Sigma-Aldrich; 
Germany). The cell suspension was incubated at 4˚C for 1 hour with gentle stirring, and snap-
frozen in dry-ice and acetone. Complete lysis was effected by 2 cycles of freeze-thawing followed 
by sonication on ice for 3-4 cycles of 1 minute pulses, at an amplitude of 80 %, pulse on for 1 
second, pulse off for 0.5 seconds (Sonoplus, Germany). The 2dCD4-containing inclusion bodies 
and other insoluble cell debris were recovered by centrifugation (10 000 x g, for 45 minutes). The 
proteins were then extracted by homogenization using a tissue homogenizer (Omni 
International, US) in a PBS-based solubilization buffer containing 8 M urea. The homogenate was 
then centrifuged at 20 000 x g for 45 min and the supernatant was purified by standard 
Page | 29  
 
immobilized metal-affinity chromatography (IMAC). To prepare the nickel-charged iminodiacetae 
sepharose 6B resin, two 15 ml falcon tubes containing 2 ml of the resin solution (1 ml resin: 1ml 
20 % ethanol) were each washed thrice with 13 ml distilled water (dH2O) and centrifuged at 1118 
x g for 5 minutes. To each tube, 10 ml of a 0.1 M NiSO4 solution was added followed by incubation 
at ambient temperature for 15 minutes with gentle agitation. The tubes were centrifuged as 
previously described above and the supernatant discarded. The resin was then washed with dH2O 
thrice before being applied to pooled lysates and incubated overnight at 4˚C with gentle stirring.  
 
Purification of the 2dCD4 protein was performed using a batch procedure. After the overnight 
incubation, the beads were centrifuged at 1118 x g for 5 minutes and the flow through discarded. 
The resin was then washed 5 times with 50 ml of wash buffer (50 mM Glycine, 2 mM β-
mercaptaethanol and 8 M Urea (pH 7.2)) containing 20 mM imidazole, and thereafter a further 5 
times with 50 ml of wash buffer containing 50 mM imidazole. The protein was eluted in 7 ml of 
wash buffer containing 500 mM imidazole.  
 
Following affinity purification, a reconstituted 2dCD4 was generated by optimized oxidative 
refolding procedures. The purified, denatured 2dCD4 protein was assembled following stepwise 
reduction of urea concentration by dialysis in a SnakeSkin® Pleated Dialysis Tubing (Pierce; 
Rockford, IL). The purified 2dCD4 protein (7 ml) was dialyzed overnight at 4 °C against 1 liter of 
folding buffer 1 (50mM glycine, 1 mM EDTA, 10 % sucrose, 1 mM reduced GSH, 0.1 mM oxidized 
glutathione (GSSG) and 4 M urea, adjusted to pH 9.6 with NaOH) and then added into 1 liter of 
folding buffer 2 (50 mM sodium carbonate, 1 mM EDTA, 10 % sucrose, 0.1 mM GSH, 0.01 mM 
GSSG, pH 9.6) for a second overnight dialysis at 4 °C with gentle stirring.  
 
This was then followed by exhaustive dialysis against PBS, pH 7.4 (three times with 2 liters, 4 h 
for the first two dialyses, and then overnight for the final dialysis at 4 °C). The dialyzed protein 
was then filtered through a 0.45 µm syringe filter, concentrated in an Amicon® Ultra-15 
Centrifugal filter device (molecular weight cut off at 10 kDa) (Millipore; Billerica, MA) and stored 
in aliquots at -80˚C. Samples were collected from the solution at various intervals and analyzed 
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by reducing and non-reducing SDS-PAGE and western blot analysis and concentration was 
determined using the Bradford assay (see Appendix 1 for procedure).  
 
2.5 Functionality testing of IBLZFab 
 
In order to test the functionality of the purified recombinant IBLZFab Enzyme-linked 
Immunosorbent Assays (ELISA), Surface Plasmon Resonance (SPR) and viral inhibition assays 
were performed.  
 
2.5.1 Enzyme-linked Immunosorbent Assay (ELISA)  
 
Maxisorp microtiter plates (Nunc, Denmark) were coated with 100 µl of 2dCD4 (1 µg/ml) 
prepared in 1 x PBS solution for one hour. The coating solution containing any unbound protein 
was then aspirated using an automated BioTek® EL X50 plate washer (BioTek® Instruments, 
Vermont). The 2dCD4-coated plates were then blocked with 300 µl Bovine Serum Albumin (BSA, 
10 mg/ml) prepared in a Phosphate-buffered Saline solution containing 1 x PBS and 0.05 % 
Tween-20 (PBS-T) overnight at 4˚C. The blocking solution was aspirated and the plate washed 
with PBS-T thrice. Following this, 100 µl of IBLZFab (1 µg/ml) was added to the bound 2dCD4 and 
incubated for 1 hour at ambient temperature in the dark. The plate was washed five times with 
PBS-T in order to discard all unbound proteins. Bound IBLZFab was detected using 100 µl of a 
horseradish peroxidase-conjugated monoclonal anti-human kappa light chain antibody 
(Amersham Biosciences), diluted 1:2000 in PBS-T and incubated for 1 hour at 4 °C. The plate was 
washed five times with PBS-T and bound IBLZFab fragments detected by adding 100 µl of Sure 
Blue™ TMB Microwell Peroxidase substrate (KPL; Gaithersburg, MD). This reaction was stopped 
by adding 100 µl of 1 M Sulphuric Acid solution. The absorbance was then read at a wavelength 
of 450 nm using a Model 680 Micro-plate reader (Bio-Rad; US).   
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Three main ELISA formats were used, and unliganded 2dCD4 (2dCD4 not associated to any 
protein complex) was used as a negative control in all ELISA experiments performed. The first 
involved binding of the periplasmic fraction of IBLZFab to 2dCD4, in order to determine whether 
the Fab fragment of interest was in fact present in the extracted periplasmic fraction. The 
complex of 2dCD4-IBLZFab was detected using horseradish peroxidase-conjugated monoclonal 
anti-human kappa light chain antibody (Amersham Biosciences, UK).  
 
The second ELISA format analyzed the binding activity of each fraction, after SEC separation, 
identifying which of the three fractions isolated contained the highest concentration of functional 
IBLZFab fragments. This ELISA involved coating WT 2dCD4 at 1 µg/ml on a 96 well Maxisorp 
microtiter plate (Nunc, Denmark), followed by binding of IBLZFab fractions at varying 
concentrations, ranging from 1 µM to 0 µM. The complex was detected using an anti-kappa light 
chain antibody at a concentration of 1:1000. The result of this experiment will not be 
compromised by the his-tag on the IBLZFab since the tag could not be detected using an anti-his 
probe (See Appendix 3).  
 
The third and final ELISA format assayed the ability of gp120 to bind to 2dCD4 in the presence of 
the bacterially expressed IBLZFab fragment. In addition, this assay aimed to determine the extent 
of CD4 induced epitope changes in gp120 in the presence of the IBLZFab fragment. A 96 well 
Maxisorp microtiter plate (Nunc, Denmark) was coated with 1 µg/ml of 2dCD4, followed by 
binding IBLZFab at 1 µg/ml and finally allowing gp120 to associate with 2dCD4, gp120-BAL was 
allowed to bind at varying concentrations ranging from 1 µM to 0 µM. The gp120-2dCD4 
complexes were detected using 2G12 and 17b.  
 
Each ELISA assay was performed in triplicate and three biological replicates were obtained for 
every assay completed. Mean and standard deviation was calculated using Microsoft excel 
(Windows 7) before evaluating any significant interactions between IBLZFab and 2dCD4.  
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2.5.2 Surface Plasmon Resonance (SPR): Analysis of the 2dCD4-IBLZFab interaction 
 
Surface Plasmon Resonance (SPR) was used to determine the kinetics of the 2dCD4-IBLZFab 
interaction. All SPR experiments were performed on a ProteON XPR 36 instrument (BioRad; US). 
For direct binding comparisons and kinetics, 2dCD4-WT was immobilized on separate flow cells 
within the same sensor chip using amine coupling according to the manufacturer’s instructions. 
Briefly, a solution of 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 
0.05 M N-hydroxysuccinimide was used to activate carboxyl groups on the sensor surface at a 
flow rate of 5 µl/min for 10 min. The recombinant 2dCD4 was prepared in a sodium acetate buffer 
(100 mM, pH 5.5) at a final concentration of 0.1 mg/ml and passed over the activated sensor chip 
surface at a flow rate of 5 µl/min until the desired immobilization level (2 500 response units) 
was achieved. Excess carboxyl groups were capped by injection of 1 M ethanolamine, pH 8.0, at 
a flow rate of 5 µl/min for 5 min. The fraction with the highest 2dCD4 binding activity as measured 
using ELISA was used in SPR studies. IBLZFab, pooled fraction 1, was passed over the 2dCD4 
surfaces at varying concentrations (from 500 nM to 0 nM) in order to obtain kinetic data. Surfaces 
with no immobilized protein were used to control for non-specific binding effects. SPR 
experiments were performed in quadruplicate and reproducibility was achieved. Surface 
Plasmon Resonance data was analyzed using the ProteOn Manager Software (BioRad; US).  Data 
was fitted to a 1:1 Langmuir binding model.  
 
2.5.3 Viral inhibition: Neutralization assays of IBLZFab 
 
In order to test the inhibiting properties of the microbially expressed IBLZFab in vitro, 
neutralization tests were performed using two pseudoviruses; CAP210 and SF162. The HEK293T 
and TZM-bl adherent cell lines were sustained in Dulbecco’s modified Eagles Medium (DMEM) 
(Sigma-Aldrich, MO, USA) supplemented with 10 % fetal calf serum (FCS) (Gibco, Life 
Technologies, US), 2 mM GlutaMax (Gibco, Life Technologies, USA), penicillin (100 units/ml) and 
streptomycin (0.1 mg/ml) (Sigma-Aldrich, US). 
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2.5.3.1 Virus amplification  
 
The antiviral efficacy of IBLZFab was obtained using an HIV-1 pseudotyped virus neutralizing assay 
previously described [90]. For the production of HIV-1 pseudoviruses HEK293T cells were co-
transfected with Env-deficient backbone expression plasmid (pSG3ΔEnv) and either SF162 LS or 
CAP210. Polyfect transfection reagent (Qiagen, Hilden, Germany) was used according to the 
manufacturer’s instructions for all transfections that were carried out in a T25 tissue culture flask 
(Nunc, Roskilde, Denmark). Briefly, 1.2 x 106 cells were seeded in a T25 flask 24 hours before 
transfection. The purified plasmid DNA (8 µg) was added to 40 µl of Polyfect in a final volume of 
500 µl of serum free media II (SFMII) (Life Technologies; US), using a ratio of 2:1 (Env: Backbone 
plasmids). The samples were mixed and allowed to incubate at ambient temperature for 5 
minutes before being added to the cells. Twelve hours later the supernatant was removed and 5 
ml of complete DMEM was added. The pseudovirus supernatant was harvested 48 hours later by 
centrifugation at 1 000 x g, FCS concentration adjusted to 20 % and thereafter viral supernatants 
filtered through a 0.2-micron syringe filter. Aliquots were stored at -80˚C.  
 
2.5.3.2 Infectivity determination of Pseudoviruses 
 
According to methods previously described [90] stored aliquots of HIV-1 pseudoviruses were 
titrated against the TZM-bl cell line in order to determine the Median Tissue Culture Infectious 
Dosage (TCID50). Using a 96 well tissue culture plate (Nunc; Denmark) a five-fold dilution series 
of each pseudovirus stock was prepared, in complete DMEM in a final volume of 100 µl. Cells 
were manually counted after being stained by Trypan Blue (Sigma-Aldrich, MO, USA) at a 1:5 ratio 
with 0.4 % of the trypan blue solution. All viable cells were then enumerated by microscopic 
inspection of the stained cell suspension using a Neubauer haemocytometer (Roth; Germany). 
One hundred microliters of 1 × 105 cells/ml containing diethylaminoethyl-dextran hydrochloride 
(DEAE Dextran) in complete DMEM were added to each well. Pseudovirus stocks were titrated 
four times and a final concentration of 20 μg/ml DEAE Dextran (Sigma-Aldrich, MO, USA) was 
added to the media.  Cells were incubated for an additional 48 hours and infectivity determined 
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by means of the tat-inducible luciferase-based reporter assay. The cell culture media was 
aspirated from each well after the 48-hour incubation and the cells lyzed by adding 100 μl of Glo-
Lysis buffer (Promega; US). After incubation of lysates at room temperature for 5 minutes, 50 μl 
of the cell lysate was transferred to a 96-well white solid luminometer plate (Promega, US) to 
which an equal volume of Bright-Glo™ Luciferase reagent (Promega; WI, USA) was added. The 
luminescence was quantified using a GloMax® Discover and Explore Detection System (Promega; 
WI, USA). The Microsoft Excel macro established by the Duke Central Reference Laboratory, 
available at the Los Alamos National Laboratory HIV immunology database 
(http://www.hiv.lanl.gov/) was used to calculate the TCID50 for each virus. 
 
2.5.3.3 Neutralization assay  
 
Viral inhibition activity of IBLZFab was assessed by the reduction in tat-inducible luciferase activity 
after a single round infectivity assay as described previously [90]. A three-fold dilution series of 
the total fraction of IBLZFab before SEC separation was prepared in a 96-well tissue culture plate 
and incubated with 200 TCID50 of HIV-1 pseudovirus particles in a final volume of 150 μl of 
complete DMEM for 1 hour at 37°C. Densitometric analysis of the total sample of IBLZFab was 
performed in order to ascertain the amount of correctly assembled, functional Fab fragment in 
the total fraction (QuantityOne version 4.6.9 software).  Samples of the total fraction of IBLZFab 
were assayed in duplicate and virus and non-virus containing wells were included as controls. 
Thereafter, 1 x 104 freshly trypsinized TZM-bl cells prepared in complete DMEM and 
supplemented with DEAE Dextran (20 μg/ml) at a final volume of 100 μl, were added to each 
well. Plates were then incubated for a further 48 hours before the luminescence was measured 
as described above. Each inhibition assay was performed in duplicate and for each assay 
triplicates were obtained for each data point, mean and standard deviation was then calculated 
using Microsoft Excel (Windows 7). The value to achieve 50 % inhibition (IC50) was calculated by 
fitting a variable-slope, non-linear regression curve using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, US).  
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3 Chapter 3: Results 
3.1 Generation of recombinant Bicistronic IBLZFab-expression vectors 
 
A bicistronic IBLZFab expression vector was designed in order to produce and purify the Fab 
fragment of an anti-HIV antibody, Ibalizumab, in a bacterial expression system. The recombinant 
cassette contained both the heavy and light chains of the Ibalizumab Fab region. The codon 
optimized cassette also contained an ompA (outer-membrane protein A) leader sequence which 
allowed the expressed protein to be transported to the periplasm where the oxidizing 
environment would support correct folding and assembly of the two chains.  
 
The IBLZFab-encoding DNA was excised from the kanamycin resistant plasmid pMK-RQ (GeneArt, 
Germany) and this DNA was then sub-cloned into the multiple cloning site (MCS) of the digested 
ampicillin resistant plasmid vector, pET15b at a 1:1 molar ratio of insert DNA: vector DNA. 
Successful ligation of vector and insert was confirmed by restriction digestion analysis and 
sequencing of the recombinant expression vector. Recombinant plasmids were isolated from 
cultured DH5α cells and subjected to digestion with BamHI and BglII. Figure 6 shows that the 
IBLZFab insert was excised from the pET15b expression plasmid using both restriction enzymes 
which resulted in a 1547 bp DNA fragment confirming the presence of the insert in the plasmid 
vector. Thereafter, expression plasmids containing the correct IBLZFab insert size were sequenced, 
verifying the correct orientation of the sub-cloned constructs (See Appendix 3).   
 
3.2 Expression and purification of IBLZFab 
 
Recombinant IBLZFab was generated by inoculating 8 litres of LB media with transformed BL21 
StarTM (DE3) E. coli cells containing the IBLZFab-pET15b expression vector. The periplasmic fraction 
of the bacterial cells was extracted before being purified by affinity chromatography.  
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Periplasmic fractions containing IBLZFab were extracted using a modified osmotic shock procedure 
previously described [91, 92]. This method involved re-suspending the cell pellet in an extraction 
buffer comprising 200 mM Tris/HCl, 1 mM EDTA, 20 % w/v sucrose and 0.5 mg mL lysozyme. E. 
coli transformed with empty pET15b vector was used as a negative control and separated 
alongside IBLZFab samples throughout the expression and purification procedure. Due to the 
impurity of the kappa matrix eluate, a second round of purification was applied in order to 
separate the unwanted bacterial proteins from the IBLZFab fragments. A high resolution Sephadex 
G-75 column was used for SEC separation of the IBLZFab. 
 
 
Despite the presence of the 6x histidine tag on the N-terminus of the Fab fragment, the expressed 
protein could not be detected on a western blot using an anti-his probe (See Appendix 3).  
Regardless of this, efforts to purify the IBLZFab using Nickel affinity chromatography were 
attempted but proved to be unsuccessful. This may be attributed to the his-tag being 
incorporated into the tertiary structure of the IBLZFab fragment. Another reason that may be 
considered is that any post-translational modification to the target protein may have removed 
the his-tag, the IBLZFab protein had been transported to the periplasm as a result of the signal 
peptide incorporated into the construct. Accordingly, purification of the Fab fragment was 
achieved using a human kappa light chain specific matrix, which associated with the light chain 
in the variable region of the Fab fragment. Analyses of the cell lysates at different steps in the 
expression and purification process revealed that some protein remained in the cytoplasmic 
fraction of the cell. The IBLZFab fragments were expressed at very low concentrations (200 µg/ml 





















Figure 6. Restriction digestion analysis of the pET15b IBLZFab expression vector: 
All DNA samples were resolved on a 1 % agarose gel, and visualized under UV light. Positive colonies 
selected from agar plates containing ligation reaction transformed E. coli were cultured overnight in LB 
broth and the recombinant plasmids were isolated. The plasmid DNA was then subjected to digestion 
analysis which resulted in DNA fragments of distinct sizes. The IBLZFab insert was excised and a DNA 
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Various periplasmic extractions were attempted since western blot analysis showed a large 
amount of expressed IBLZFab retention in the cytoplasmic fraction of the cell lysates. Protein yield 
was increased by treatment on ice as well as treatment with ice cold dH2O.  Samples of total cell 
lysate and periplasmic fractions were analyzed by reducing and non-reducing SDS-PAGE and 
western blot. The negative control used in western blot analyses of IBLZFab expression and 
purification was E. coli transformed with empty plasmid vector pET15b, deficient of a protein 
encoding insert.  
 
SDS-PAGE Coomassie stains were inconclusive therefore western blot analysis was performed. 
The Fab fragment existed in two forms; assembled Fab fragments observed at a molecular weight 
of ~50 kDa (heterodimers) and unassembled monomers with a size of ~25 kDa.  The negative 
control used in all experiments illustrated banding patterns that were similar to that of the 
recombinant IBLZFab-encoding pET15b plasmid (See Appendix 3). However western blot analysis 
showed a distinct difference in purified eluents (Figure 7). Despite the non-specific binding of the 
anti-kappa light chain antibody, western blot analysis shows the presence of the Fab fragment in 
the IBLZFab periplasmic fraction and eluent, at ~50 kDa, under non-reducing conditions, with no 
detection in the negative control (Figure 7). 

















Figure 7. Western blot analysis of IBLZFab expression and purification under non-reducing conditions: 
IBLZFab was detected using a human kappa light chain specific antibody (diluted 1:500). The antibody associated with the human kappa light chain 
on the variable region of the Fab fragment. A non-recombinant pET15b, was analyzed alongside the fragments as a negative control. Western blot 
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3.2.1 Size exclusion chromatography 
 
In order to increase the homogeneity of the affinity purified IBLZFab, the total fraction was 
subjected to size exclusion chromatography (SEC). The total IBLZFab fraction was applied to a 
Sephadex G-75 AKTA-FPLC P-920 column. Fractions contained in the same protein peak were 
pooled and analyzed. The separation resulted in three main fractions of interest; pooled fractions 
1, 2 and 3 as well as the ~10 kDa contaminating bacterial protein (Figure 8 A). IBLZFab molecular 
weights represented by the peaks were determined based on the Gel filtration Low Molecular 
Weight (LMW) calibration kit (GE Healthcare; UK) which was applied to the column, before the 
total fraction of IBLZFab was separated, to illustrate where peaks of specific sizes would be eluted 
(Appendix 3). F1 and F2, seen in Figure 8 A, was not active despite being tested by ELISA analysis 
and correspond to the void volume based on the calibration curve. The Ibalizumab Fab 
fragments, in pooled fraction 1, correspond to a predicted size of ~50 kDa. Fractions were 
resolved using non-reducing 12.5 % SDS-PAGE to determine which fraction contained the Fab 
fragment (Figure 8 B). Western blot analysis of these fractions seen in figure 8 C confirms the 
presence of the IBLZFab fragment in fraction 1. Pooled fraction 1 appeared to contain the highest 
amount of Fab fragment detected by the anti-kappa light chain specific antibody, followed by 
fraction 2.  The monomeric or unassembled chains are visible in pooled fraction 3. The negative 
control resolved alongside the fractions of interest is a 10 kDa bacterial protein, present within 
the total fraction of IBLZFab, which has been consistently expressed. This protein was not detected 
using a kappa light chain specific antibody and was therefore used as a negative control. 
Subsequent to SEC separation ~200 µl at a concentration of ~200 µg/ml of functional, assembled 
IBLZFab could be isolated.













Figure 8. Elution profile of SEC separation on a Sephadex G-75 column, SDS-PAGE and western blot 
analysis of IBLZFab 
Figure 8 A illustrates the elution profile of the IBLZFab. Pooled fraction 1 (indicated by red bracket), pooled fraction 2 
(green bracket) and pooled fraction 3 (blue bracket) correspond to molecular weight sizes of ~50 kDa, ~50/25 kDa 
and ~25 kDa respectively. This is based on LMW standards seen in appendix 3, maximum elution volumes of 
conalbumin, ovalbumin and carbonic anhydrous are indicated by black arrows on the figure. Fractions were collected 
at 3 ml intervals, those constituting one peak were pooled and concentrated. Figure 8 B is a non-reducing SDS-PAGE 
analysis of SEC separated fraction (F3 to F10 and F19-F20). Fab fragments are visible in F3 and F4, and the bacterially 
expressed ~10 kDa is seen in F19 and F20. These fractions correspond to the elution profile in Figure 8 A. Figure 8 C 
is the western blot detection of SEC separated IBLZFab fragments using anti-kappa light chain specific antibody 
(diluted 1:500) confirms the presence of the IBLZFab fragment in fraction 1 and 2 and the monomeric or unassembled 
chains in fraction 3.  The bacterially expressed ~10 kDa protein is not detected by a kappa light chain specific 
antibody. 
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3.3 Functionality testing of IBLZFab 
 
The integrity and binding capacity of IBLZFab was tested using ELISA and SPR analysis. The viral 
inhibition efficacy of the Fab fragment was also tested using viral neutralization studies.  
 
3.3.1 Enzyme-linked Immunosorbent Assay (ELISA) Analysis of IBLZFab 
 
Three main ELISA formats were used. The first ELISA involved binding the total, affinity purified 
fraction of IBLZFab to 2dCD4 in order to determine whether the Fab fragment associated correctly 
with 2dCD4. The highest signal was observed at the highest concentration and the weakest at 
the lowest concentration of the total fraction of IBLZFab. For improved separation of IBLZFab, a 
Sephadex G-75 column was used. The SDS-PAGE analysis of these fractions indicated that the 50 
kDa Fab fragment was most likely in pooled fraction 2 (See Appendix 3). However, ELISA analysis 
showed that the most active fraction with the highest concentration of functional Fab fragment 
was pooled fraction 1 (Figure 9), concentration was determined by means of the BCA assay (see 
Appendix 1). The binding by pooled fraction 1 is vastly greater than that of the total fraction 
before SEC separation.  




Figure 9. Detection of IBLZFab bound 2dCD4: 
The 2dCD4-IBLZFab complex was detected with an anti-kappa antibody. Each experiment was performed in triplicate to obtain an average 
absorbance, standard deviation was also calculated (refer to error bars within the figure). Fraction 1, seen in pink has the highest signal at the 
highest concentration compared to the other fractions, indicating it is the most active fraction. Fraction 2 in purple and fraction 3 in green are not 
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Ibalizumab is non-immunosuppressive and does not hinder the binding of viral gp120 proteins to 
CD4. In order to test the functionality of this microbially expressed IBLZFab an ELISA was 
performed to detect the binding of gp120 to WT 2dCD4 in the presence of IBLZFab. Figure 10 
shows that the microbially expressed IBLZFab does not prevent gp120 from binding to 2dCD4. The 
interaction between gp120 and CD4 was confirmed by the signal produced by 2G12, a 
monoclonal antibody that recognizes a distinct neutralization epitope on the gp120 glycoprotein 
of HIV-1 [93]. The 2G12 epitope is mannose dependent and is located on the high-mannose 
glycans of residues 295, 332, and 392, with peripheral glycans from residues 386 and 448 on 
either side [94]. This epitope is believed to have no direct contact with the gp120 polypeptide 
surface.  
 
A strong signal is also produced when detecting with 17b (Figure 10), an antibody that binds the 
CD4-induced form of gp120 (CD4i). The absorbance signal produced when detecting with 17b 
was observed in the 2dCD4-gp120 complex in the presence and absence (negative control) of the 
IBLZFab fragment. The CD4i form of gp120 facilitates co-receptor binding; inhibition by Ibalizumab 
does not prevent this interaction. The structural integrity within domain 1 and domain 2 of CD4 
is not essential for HIV-1 entry or inhibition by Ibalizumab. Freeman et. al. [75] showed that it is 
therefore unlikely that Ibalizumab would directly block gp120 binding to the co-receptor on the 
cell surface. It is believed that the binding of Ibalizumab affects downstream conformational 
changes that ultimately prevent viral entry into the host cell [75].  
 
The results seen in Figure 10 support the objective of this study, affirming the fact that the protein 
which has been successfully expressed and purified in a bacterial expression system does not 
impair the binding of gp120 to 2dCD4 and does indeed bind to 2dCD4 in the presence of gp120. 
Based on sequence analysis of the construct this protein corresponds to the Fab fragment of 
Ibalizumab (Appendix 2). It can be concluded that this protein associates with CD4 at an epitope 
away from the binding site of gp120 and MHC class II molecules.




Figure 10. Detection of the interaction between WT 2dCD4 and gp120-BAL in the presence of IBLZFab: 
The interaction of gp120 and 2dCD4 in complex with IBLZFab was detected using a gp120 specific antibody, 2G12 (yellow) and a gp120 CD4 induced 
site specific antibody, 17b (green). Each experiment was performed in triplicate to obtain an average absorbance, standard deviation was also 
calculated (refer to error bars within the figure). The signal seen in blue is that of the kappa light chain specific antibody, illustrating the presence 
of the Ibalizumab Fab fragment in the complex, this decreased signal may be due to the presence of gp120 in the complex.  Controls deficient of 
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Page | 46  
 
3.3.2 Surface Plasmon Resonance (SPR) Analysis of IBLZFab 
 
The kinetics of the IBLZFab-2dCD4 interaction was tested using SPR. The fraction with the highest 
2dCD4 binding activity, fraction 1, as measured using ELISA was used in SPR studies. Purified 
2dCD4-WT was immobilized on a GLC sensor chip. Total fraction concentration was used to 
prepare samples from 250 nM to 0 nM. Due to the contamination seen in the SDS-PAGE analysis 
(See Appendix 3), densitometry could not be performed on the sample. The association rate (ka), 
dissociation rate (kd), and equilibrium dissociation (KD) constants for the reaction between 2dCD4 
and IBLZFab were calculated by fitting the resultant sensograms directly to a 1:1 Langmuir binding 
model using the ProteON Manager software. The calculated affinity for the interaction between 
2dCD4-WT and IBLZFab was 11.3 nM, similar to KD values published by others [95] (Figure 11). 

















Figure 11. 2dCD4-IBLZFab interaction analysis by SPR: 
Microbially expressed IBLZFab at concentrations ranging from 250 nM down to 0 nM were passed over immobilized 2dCD4 (0.1 mg/ml) at a flow 
rate of 5 µl/min for 5 minutes. A KD value of 11.3 nM was calculated, with an association constant (ka) of 2.02 x 104 Ms-1 and a dissociation constant 
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3.3.3 Viral inhibition: Neutralization Assays of IBLZFab 
 
In order to test the inhibiting properties of the microbially expressed IBLZFab in vitro, in house 
neutralization assays were performed using two pseudoviruses; CAP210 and SF162. The total 
fraction IBLZFab was used in the neutralization assays since obtaining a satisfactory concentration 
of the pure IBLZFab proved challenging. 
 
The total fraction of IBLZFab was used at final concentration of 125 µg to account for the 
contaminating proteins present in the preparation. Based on the densitometric analysis of the 
SDS-PAGE non-reducing coomassie gel, of the total fraction, approximately 13.97 % appeared to 
be correctly assembled IBLZFab (Figure 12). Since only the 10 kDa protein eluted with the Fab 
fragment using the anti-kappa specific matrix and did not exhibit any activity in ELISA analyses, it 
was used as a negative control in order to confirm that any inhibition seen in the assays were 
indeed from IBLZFab. The 10 kDa protein was extracted and co-purified with the total fraction of 
IBLZFab. A pure sample of this protein was then obtained through SEC separation of the total 
fraction of the fab fragment (Figure 8).  
 
Enfuvirtide or T20 is a fusion inhibitor, which disrupts the formation of the 6HB thereby preventing 
virus entry into the host cell. T20 was used as a positive control to ensure the assay was functional 
(Figure 13 A). In addition, IBLZFab was able to neutralize approximately 50 % of pseudovirus 
CAP210 and ~20 % of pseudovirus SF162 (Figure 13 B). No inhibition was detected with the ~10 
kDa negative control, attributing all neutralization activity to active IBLZFab fragment. VSV-G was 
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Figure 12. Non-reducing SDS-PAGE Analysis of 3 µg of total fraction of IBLZFab: 
The total fraction of IBLZFab (3 µg) was separated under non-reducing conditions, this image depicts the 
Fab fragment at 50 kDa (indicated by the red arrow), unassembled chains at 25 kDa (indicated by the blue 
arrow) and a 10 kDa contaminating protein (indicated by the green arrow). The co-purified 10 kDa protein 
was used as the negative control in neutralization assays. According to densitometric analysis 
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Figure 13. Neutralization Assay of pseudoviruses CAP210, SF162 and VSV-G against entry inhibitor 
Enfuvirtide (T20) and IBLZFab: 
T20 was used as a positive control and tested alongside each pseudovirus challenged with IBLZFab; 
reproducibility of the control in each assay was successful. Graph 13 A illustrates the average viral percent 
inhibition of CAP210 by entry inhibitor T20 and IBLZFab (seen in blue and red, respectively), 100 % inhibition 
with T20 was achieved at 20 µg/ml, the highest concentration of T20. An acceptable IC50 value of 
approximately 0.36 µg/ml was obtained. Neutralization of CAP210 by IBLZFab achieved 50 % viral inhibition 
(seen in red) at the highest concentration of the total fraction of IBLZFab, 125 µg/ml. The 10 kDa protein 
used as a negative control showed no activity (seen in grey) or inhibition. Graph 13 B illustrates the 
average viral percent inhibition of SF162 by IBLZ and T20.  Neutralization of IBLZFab against SF162 achieved 
~20 % viral inhibition seen in red. T20 obtained 100 % inhibition (visible in blue). Graph 13 C depicts the 
negative control of VSV-G run alongside all neutralization assays, no neutralization was observed by the 
IBLZ fraction (in red), confirming neutralization data obtained from the assay is attributed to the active 
fraction containing functional IBLZFab fragments. 
A B 
C 
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4 Chapter 4: Discussion and Concluding remarks 
 
Ibalizumab is a humanized anti-CD4 monoclonal antibody with potent HIV-1 inhibitory effects 
and has been FDA approved as an anti-HIV-1 therapeutic agent [96]. This study investigated the 
feasibility of expressing a functional Ibalizumab Fab fragment using a microbial expression vector.  
 
Despite the relatively high production costs of mammalian antibody production, approximately 
95 % of all currently available therapeutic antibodies are still produced in mammalian cell culture 
systems [85]. Folding, secretion and post-translational modification observed in mammalian 
expression systems produce antibodies which are comparable to those produced by the human 
body [85]. In the case of commercially available antibodies as therapeutic agents, production 
requires a significant increase in yield. For instance, in some high-dose antibody therapies that 
require more than 200 kg of purified product, the costs may exceed $500/g of protein per annum 
supposing a productivity of 2 g/L with a 50 % process yield [44]. 
 
Bacterial expression systems are unquestionably more cost effective and allow expression of 
antibody fragments such as Fab and scFV fragments [44]. In contrast to the cost of mammalian 
protein expression, bacterial cell culture and purification reagents cost around $1000 for 
approximately 50 liters of cell culture media. As an example, the commercially available digoxin 
Fab fragment, DigiFab, used for the treatment of digoxin intoxication is expressed in Gram 
negative E. coli cells [97] much like this study. Over expression of the Digoxin fab fragment is 
temperature induced, and a protein yield of 0.8 mg/L is achieved through the shake flask 
expression system [85]. Not all Fab fragments, such as IBLZFab, are able to express under the same 
conditions and require independent optimization. E. coli has always been the favored expression 
system for recombinant protein production, which can be attributed to the many advantages this 
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system offers apart from being cost effective. These include high growth rate, simple cell media 
requirements, ease of handling and high yield [98].  
 
Bacterial cells are not an ideal expression system for the production of antibodies as these are 
complex polyproteins [99]. However, bacterial expression of certain antibody fragments can be 
achieved by export of the heavy and light chains to the periplasm for correct folding and 
formation of disulfide bonds [99]. Signal peptides in E. coli are used to transport pre-proteins 
from their point of synthesis to their final localization through various secretory pathways [92]. 
One such signal that has been employed in bacterial protein expression is the ompA signal 
sequence. The unfolded translated heavy and light chains, in the cytoplasm, are targeted by the 
N-terminal ompA secretion signal which directs the polypeptides to the periplasm via the 
secretory-dependent transport pathway [100]. Upon secretion to the periplasm the ompA signal 
sequence is cleaved by resident peptidases and the Fab fragment chains are allowed to assemble 
[101]. In the periplasm, disulfide oxidoreductases and isomerases catalyze the formation of 
disulfide bonds between the heavy and light chains, enabling the accumulation of correctly 
folded, soluble Fab fragments [102]. Therefore, successful bacterial expression of an effective 
anti-HIV monoclonal antibody such as Ibalizumab will have a significant impact on antibody 
therapeutic approaches in countries like South Africa.  
 
One approach that may be employed for the bacterial production of the Ibalizumab fab fragment 
in E. coli is the independent expression of the heavy and light chain; IBLZH and IBLZL. Individual 
expression vectors may be designed, consisting of either the IBLZH chain or the IBLZL chain. 
Expressed chains may then be extracted from harvested bacterial cells and purified using a well-
established affinity chromatography procedure. Following affinity purification of IBLZH and IBLZL, 
a reconstituted fab fragment may be generated by optimized oxidative refolding procedures. An 
alternative approach that was applied in this study, is the bicistronic expression of the IBLZFab. 
This involved co-expression of the IBLZVH, IBLZCH1 and IBLZVL, IBLZCL on a single plasmid which 
allowed in vivo reconstitution in the presence of protein folding enzymes in the periplasmic 
environment. This approach has been documented to be more efficient than in vitro 
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reconstitution, and potentially improved the quality of the recombinant protein despite the poor 
yield [103]. The banding patterns on the SDS-PAGE gels of the periplasmic fractions, shown in 
appendix 3, are typical for antibody expression in E. coli documented in the literature [43, 91, 99, 
104]. 
 
According to some of the literature [43, 44, 85, 91] the best approaches to expressing functional 
antibody fragments in bacteria take advantage of its secretory system. This process, first 
described in 1988 [105],  allows correct folding of the Fab fragment by exporting the translated 
light and heavy chains of the Fab to the oxidative environment of the periplasm resulting in the 
correctly folded heterodimer Fab. Fab fragments that are secreted to the periplasm for correct 
folding usually result in low yields, but expression in the reducing environment of the cytoplasm 
results in non-functional or unfolded protein chains [106].  
 
Optimal protein expression of the Ibalizumab Fab fragment was achieved in the absence of 
isopropyl-1-thio-β-D-galactopyranoside (IPTG). IPTG serves as a mimic of the naturally occurring 
allolactose that is an inducer of the lac operon. IPTG is often used at final concentrations ranging 
from 0.5-1.0 mM. Reports on induction strategies show highest Fab yields were obtained by 
induction with low IPTG concentration [107]. However, over expression of the Fab fragment, with 
the bacterial expression methods applied in this study, remained consistent in the presence and 
absence of IPTG. This was due to ‘leaky’ transcription initiated by the T7 promoter in the plasmid 
vector. Therefore, induction of the over expression of the Ibalizumab Fab fragment in this study 
occurred in the absence of IPTG.  
 
Non-specific bacterial proteins co-purified with the assembled and unassembled Fab fragments. 
The co-purification of these bacterial proteins could be attributed to unoccupied binding sites on 
the kappa matrix resin. The large amounts of periplasmic extraction lysate required for obtaining 
an acceptable amount of the low yield fab fragment and poor binding efficiency of the Fab 
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fragment, may have contributed to the non-specific binding of these bacterial proteins to the 
matrix.   
 
The elution profile (seen in Figure 8) of IBLZFab indicates the absorbance (mAU) of the 
heterodimeric form of the protein at ~8 mAU, consistent with the findings of others [81]. The 
aforementioned study, conducted by Pace, et. al. created Ibalizumab based bi-specific broadly 
neutralizing antibodies (biNAbs) by fusing the scFv of PG9 and/or PG16 to the N-terminus of the 
heavy chain of Ibalizumab [81]. The biNAbs were expressed in 293A cells and SEC separation was 
applied in order to obtain the functional, heterodimeric antibody (~50 kDa) from the cell lysate. 
The elution profile of the biNAbs including unconjugated Ibalizumab, which was used as parent 
control, was consistent with the findings of this study.  
 
Low amounts of functional IBLZFab were recovered from the periplasmic fraction of the bacterial 
cell. The efficiency of Fab fragment production in E. coli varies between different cell strains and 
growth conditions [43]. A single protein located in the periplasm of E. coli  (Skp) has been shown 
to increase the over expression of fusion proteins, [108]. Skp is a chaperone protein, believed to 
be involved in the transport of outer-membrane proteins, such as the ompA signal sequence 
[109]. Skp is expressed at varying levels in different E. coli strains [43]. A study led by Corisdeo et. 
al. showed that E. coli strains JM105 and BL21 produced the highest levels of Fab fragment 
recovered [43]. Therefore, the difference of Fab fragment yield may be attributed to the amount 
of Skp proteins produced during over expression, transport and folding of the proteins [43]. This 
study made use of the BL21 E. coli strain and ompA signal sequence, in order to increase the yield 
of the recombinant Ibalizumab Fab fragment.  
 
The poor Fab fragment yield could also be related to the excess strain of the bacterial secretory 
system [99]. Robust expression systems are usually preferred, so as to gain maximal yield of 
recombinant proteins [99]. However, using these strong expression systems exerts a tremendous 
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metabolic stress on the host cell metabolism [110]. The use of powerful induction promoters, 
such as the T7 promoter used in this study, when expressing Fab fragments in E. coli overloads 
and saturates the host’s secretory system [99]. This saturation of the secretory system may be 
one of the reasons that poor yields of the recombinant IBLZFab fragments were recovered. Even 
so, functionality tests were performed in order to test the binding capacity and the viral efficacy 
of the Fab fragment.  
 
Functionality of the bacterially expressed IBLZFab were investigated by: (1) ELISA analysis to test 
the modular association of IBLZFab and 2dCD4; (2) SPR analysis to ascertain the binding kinetics of 
IBLZFab to 2dCD4, and (3) viral inhibition assays to evaluate the neutralization efficacy of 
bacterially expressed IBLZFab. 
 
The non-immunosuppressive properties of Ibalizumab make it a favourable candidate for anti-
viral therapy. It has a distinct epitope from other anti-CD4 molecules by binding to the interface 
of D1 and D2 of CD4 away from the binding site of MHC class II molecules [17, 75, 76]. ELISA 
analyses were performed to test whether the Fab fragment expressed in bacteria exhibited the 
same binding capacity (see Figure 9). In addition to IBLZFab associating with CD4, the binding of 
gp120 to WT 2dCD4 in the presence of IBLZFab was also assessed (refer to Figure 10). IBLZFab 
should not obstruct the binding of viral gp120 proteins to CD4 [75]. Analyzing the efficiency of 
17b uptake provides an additional control for the quality of the gp120-CD4 interaction in the 
presence of IBLZFab.  
 
The calculated affinity for the interaction between 2dCD4-WT and IBLZFab by SPR analysis was 11 
nM. For the bivalent form of Ibalizumab, KD values range from 4.3 nM to even low picomolar 
values. The efficiency of viral inhibition of the bivalent IgG and monovalent Fab fragments vary 
greatly among different viral isolates [75].  Still, both the IgG and Fab fragment of Ibalizumab can 
block infection [75]. 
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The impressive CD4-binding kinetics and HIV-neutralizing properties of Ibalizumab led Pace et. 
al. to develop a bispecific bNAb (biNAb) that combines the efficacy of Ibalizumab with anti-gp120 
bNAbs [81]. The study assessed the binding affinities of the biNAbs (PG9-IBLZ) as well the parent 
antibodies (PG9 and Ibalizumab) by SPR. The analytes used in the SPR experiment included 
soluble CD4 and gp120 (BaL strain) [81]. A KD value of 15 nM, for the parent Ibalizumab antibody 
associated to CD4, was reported [81]. The findings of this study is consistent with data published 
by others [81], approving the binding affinity of the bacterially expressed recombinant IBLZFab.  
 
Two of the biNAbs designed (PG9-Ibalizumab and PG16-Ibalizumab) exhibited extraordinary 
breadth and potency, neutralizing 100 % of the 118 tier 2 and 3 viruses tested. The viral activity 
of Ibalizumab based biNAbs are the only antibody-like molecules thus far that are able to 
neutralize 100 % of all viruses tested at low picomolar concentrations [81]. This enhanced activity 
is said to be due to the mechanism of action of Ibalizumab, by associating with the ectodomain 
of CD4, it anchors the biNAb to the infected cell allowing viral inhibition through synergistic 
activity of the two molecules [81]. The viral inhibition by this biNAb, PG9-IBLZ, is said to be 
enhanced not only through the action of the two active agents working in concert but the longer 
reach of the anti-Env scFv on the fusion molecule [81]. It is believed to permit bivalent binding of 
more than one gp120 molecule on the surface of the virus, this results in improved antibody 
affinity and ultimately viral neutralization [81]. The conjugation of Ibalizumab to PG9 is also said 
to anchor the biNAb to CD4 at the cell surface allowing the inhibitory activity to be concentrated 
at the required site [81]. Obtaining binding affinity values comparable to that of the literature 
confirms that microbial expression of the Ibalizumab Fab fragment is not only possible but binds 
to CD4 with the same affinity as mammalian expressed IBLZFab fragments. This supports the main 
objective of this project.  
 
Single-round in vitro infectivity assays were performed to provide a quantitative measure for 
evaluating the neutralization activity of the bacterially expressed IBLZFab fragments. Two HIV-1 
Env-pseudotyped viruses, SF162 and CAP210 were chosen in order to evaluate the reproducibility 
of the data published by others [75].
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The IC50 values of the Ibalizumab Fab fragment ranges between 0.02 – 0.16 µg/ml [17]. The 
neutralizing activity seen against SF162 was consistent with that of published data, at a 
concentration of >100 µg/ml pure Ibalizumab was able to neutralize ~24 % of SF162 [75].  The 
data obtained in this experiment cannot be directly compared to published data since a pure 
sample of IBLZFab fragment was not used.  
 
The main objective of the viral inhibition studies was to evaluate whether the Fab fragment had 
any detectable neutralization activity. Even though neutralization activity was obtained at a high 
concentration the bacterially expressed IBLZFab fragment was able to inhibit viral entry. 
 
4.1 Concluding Remarks 
 
This study illustrates the possibility of expressing and purifying functional Ibalizimab Fab 
fragments using a bacterial expression system. Despite this, it does not seem feasible to produce 
this recombinant antibody fragment in the E. coli system adopted in this study, as the yield is very 
low and the purification processes involved are both time consuming and laborious.  
 
E. coli is one of the most important recombinant protein expression hosts used, though antibody 
expression proves challenging since these organisms do not have the necessary cellular 
machinery to glycosylate proteins [44]. Traditionally monoclonal antibodies are produced in 
mammalian cell culture mostly due to functional motifs within the Fc region of the antibody, 
which are responsible for effector ligand recruitment [44, 111], that require the presence of an 
accessible carbohydrate structure at Asn297. Mammalian expression systems, unlike bacterial 
expression systems, are equipped with the necessary cellular machinery required to generate 
these oligosaccharides which are analogous to those produced in the human body [44]. 
Mammalian cell lines are the leading expression systems for recombinant antibody production 
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[85]. Still, alternative production systems may be used to decrease the cost of antibody 
expression. Apart from bacterial expression systems, some cost effective methodologies include 
eukaryotic expression systems distinct from mammalian cell lines that are able to produce 
recombinant antibodies. These include yeast, protozoa, filamentous fungi and even transgenic 
plants and animals [85].  
 
Yeast cells combine the ability of both eukaryotic as well prokaryotic expression systems with a 
short generation time and ease of genetic manipulation in addition to simple media requirements 
and stability much like microbial hosts [112]. In recent times, a multicellular parasite Leishmania 
tarentolae has been tested as an expression system for various recombinant proteins [113, 114]. 
Some of these include amylase, green fluorescent protein [115] and even HIV-1 gag proteins 
[116]. This protozoan organism has the ability to mimic mammalian glycosylation and is able to 
perform N- and O-glycosylation; both processes are highly conserved in mammalian cell lines 
[113, 117]. This system can be adapted for large up-scaling, it has easy genetic manipulation, and 
has minimal nutrition requirement [113]. As a result L. tarentolae is being explored for the 
production of recombinant antibodies [118].  
 
Another area that is being explored for the expression of recombinant antibodies is transgenic 
plants [85]. Plants are able to perform the necessary post translational maturation required for 
the functional biological activity of therapeutic proteins [119].  This expression system allows cost 
effective up-scaling of production, though plants lack the processing machinery required for 
authentic N-glycosylation patterns which pose a challenge since enormous amounts of plant 
material may have to be processed [120]. Expression, folding and assembly may involve the 
expression of the heavy and light chains in a single plant or two individual plants [119]. Expression 
can be initiated by the co-transformation of separate gene cassettes or by a single expression 
cassette [121]. For increased expression levels or to establish a transgenic line, expression may 
be manipulated depending on the specific requirements of the mAb of interest [121]. In order to 
avoid the unbalanced expression of the heavy and light chains, careful selection of regulatory 
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elements such as the promoter and terminator is crucial [121]. Some successfully expressed 
therapeutic antibodies, vaccines and antigens in plants for infectious diseases include HIV-1 tat 
protein expressed in Spinacea oleraceae [122], rabies peptide expressed in Nicotiana tabacum 
[123], smallpox B5 antigenic domain expressed in Brassica oleracea [124], hepatitis B core protein 
expressed in Nicotiana tabacum [125] and severe acute respiratory syndrome (SARS) spike 
protein and virus fragments also expressed in Nicotiana tabacum have been reported [126].  
 
Recently, a group of researchers were able to express and purify 2G12 in transgenic tobacco 
plants that were subsequently accepted by the UK national pharmaceutical regulator [127]. An 
in-human, placebo-controlled, double blind phase I safety study of plant-derived 2G12 was then 
conducted, the first of its kind [127]. The antibody yield in the T1 generation was approximately 
10 µg/g but increased and stabilized to ~25 µg/g in the T5 generation [127]. HIV-1 neutralizing 
antibodies such as 2G12 are used as immunoprophylaxis, therefore large doses of these proteins 
are required for effective protection [128]. In order to keep up with the global demand the 
production capacity is required to exceed 1000 kg/year [128]. The demand for these products 
are primarily in developing countries therefore costs need to be kept low, this in turn means 
conventional manufacturing approaches cannot be effected [127]. Plant-based engineering is 
consequently an attractive approach due to the low cost and scalability [127].  
 
To date, mammalian cell lines are the most widespread expression systems for recombinant 
therapeutic antibodies. Other approaches that may be employed to decrease cost do not always 
result in the expression of a fully functional antibody but can be used in some in vitro applications 
such as research and diagnostics, where glycosylation patterns do not play a pivotal role [85]. 
Since Ibalizumab is a therapeutic antibody the integrity of this mAb is essential for its anti-HIV 
activity, correct folding and assembly of the effector domain is crucial. It is worth mentioning that 
no expression system will guarantee the production of high yields of antibody since every 
molecule comes with its own challenges [85]. 
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Appendix 1: Customary Protocols and Recipes 
Solutions for bacterial culture 
Luria-Bertani (LB) Broth (1L) 
10 g Tryptone powder (OxoidInc; Basingstoke, Hampshire, England), 5 g of yeast extract powder 
(BioLab; Wadeville, Gauteng, South Africa) and 5 g of NaCl were dissolved in dH2O to a final 
volume of 1 L. the broth was autoclaved at 121˚C, 1 kg/cm2 for 20 minutes and stored at ambient 
temperature until use. 
Agar plates 
7 g of agar powder was added to 200 ml of dH2O and autoclaved at 121˚C, 1 kg/cm2 for 20 minutes 
and stored at ambient temperature until use. When used the agar was warmed in the microwave 
and the appropriate antibiotics were added at 100 mg/ml, poured into 90 mmm petri dishes and 
allowed to set.  
Ampicillin stock (100 mg/ml) 
1 g of ampicillin (Sigma-Aldrich; Germany) was dissolved in 70 % Ethanaol to a final volume of 10 
ml and stored at -20˚C until use. 
Transformation buffer (100mls) (for chemically competent cells) 
1.4702 g of CaCl2.H2O (100 mM), 0.3024 g of PIPES.HCl (10mM) (Boehringer Mannheim; GmBh, 
Germany) and 15ml glycerol (15 %) were mixed with dH2O to a final volume of 100 ml. the pH of 
the solution was adjusted to 7.0 using 10 M NaOH. The solution was then autoclaved and stored 
at -20˚C until use.  
Preparation of competent bacterial cell (DH5α and BL21 (DE3) stars 
20 ml of LB broth was inoculated with 10 µl of DH5α (Novagen; Germany) and BL21 (DE3) stars 
stock, under sterile conditions. The cultures were incubated overnight at 37˚C in an orbital 
shaker. The overnight cultures were diluted 1:40 in LB broth and grown for 2 to 3 hours at 37˚C 
in an orbital shaker to stimulate log phase growth. Once the A600 readings reached 0.4, cells were 
then harvested at 1000 x g for 20 minutes at 4˚C. The cell pellet was then resuspended in 10 ml 
ice cold transformation buffer and incubated on ice for 20 minutes. The cells were then harvested 
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once again and the cell pellet resuspended in 1 ml transformation buffer. 100 µl aliquots were 
prepared, snap-forzen in acetone and dry ice then stored at -80˚C until use.  
Transformation of competent E. coli cells 
1 µl (~50 ng) of plasmid DNA or 10 µl of ligation reaction was added to 50 µl of competent E. coli, 
the mixture was incubated on ice for 20 to 25 minutes. A negative control was set alongside, 
containing no plasmid DNA. Cells were heat shocked at 42˚C for 30 seconds and immediately 
incubated on ice for 2 minutes. Each transformation reaction was spread onto an agar plate with 
the appropriate antibiotic, under sterile conditions and incubated at 37˚C overnight.  
Solutions for Agarose Electrophoresis 
0.5 M EDTA (Ethelynedianine Tetra-acetic Acid) (pH 8.0) 
93.05 g of EDTA powder was dissolved in dH2O to a final volume of 500 ml. The pH was adjusted 
to 8.0 using 10 M NaOH. It was autoclaved and stored at room temperature until use.  
50 x TAE Buffer  
242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA were added to dH2O to a final 
volume of 1 L and stored at room temperature until use. The solution was diluted to a 1 x buffer 
before use using dH2O.  
Preparation of agarose gels 
0.8 % or 1 % agarose gels were prepared by adding either 0.8 or 1 g of agarose powder to 100 ml 
of 1 x TAE buffer. The mixture was then heated until the agarose dissolved. Before pouring the 
gels, 5 µl of ethidium bromide (Promega; Madison, WI) was added. Gels were poured and allowed 
to set in a Bio-Rad Gel chamber system (Bio-Rad; Gercules, CA).  
Electrophoresis Procedure 
The agrose gels were resolved in a Bio-Rad Gel Tank system (Bio-Rad; Hercules, CA) and 
submerged in 1 x TAE buffer, allowing for even heat conduction. All DNA samples, comtrols and 
DNA ladder wer mixed with DNA loading buffer. The voltage was set at 30 V till the samples had 
keft the wells and increased to 80 V until the gel had completely resolved. DNA bands on the gels 
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were visualized using a Universal Hood Gel Doc and the Quantity One Software Programme (Bio-
Rad; Hercules, CA). 
Protein purification 
Solutions for protein Purification of 2dCD4 
M Nickel Sulphate (NiSO4) 
5.257 g of NiSO4 was added to 200 ml dH2O and stored at room temperature until use.  
2 M Sodium Hydroxide (NaOH) 
8 g of NaOH was dissolved in 100 ml of dH2O, autoclaved and stored at room temperature until 
use.  
0 mM Imidazole purification buffer  
1.86 g of glycine, 70 µl of β-mercaptaethanol, 14.61 g NaCl and 240 g of urea were mixed in dH2O 
until a final volume of 500 ml was reached. The buffer was stored at room temperature until use.  
500 mM Imidazole buffer (pH 7.4) 
1.86 g of glycine, 70 µl of β-mercaptaethanol, 14.61 g NaCl, 17 g of imidazole powder and 240 g 
of urea were mixed in dH2O until a final volume of 500 ml was reached. The buffer was stored at 
room temperature until use.  
In vitro Folding Buffer A (pH 9.6) 
3.75 g glycine, 100 g sucrose, 2 ml 0.5 M EDTA, 0.31 g GSH, 0.06 g GSSG, 240 g urea and 2.8 ml 
2M NaOH were mixed in Milliq water until a final volume of 1 L was reached. The solution was 
made prior to folding.  
In vitro Folding Buffer B (pH 9.6) 
1.59 g of Sodium Carbonate, 2.93 g of Sodium Bicarbonate, 100 g sucrose, 2 ml 0.5 M EDTA, 0.031 
g GSH and 0.006 g GSSG were mixed in MilliQ water until a final volume of 1 L was reached. The 
solution was made prior to folding. 
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Preparation of columns for purification procedures 
Nickel-charged sepharose 6B resin was used to purify 2dCD4. The histidine tag attached to the C-
terminal end associated with the charged nickel resin. Two 15 ml falcon tubes with 1 ml of packed 
resin were washed with dH2O three times and centrifuges at 3500 rpm for 5 minutes. Ten 
milliliters of 0.1 M NiSO4 solution was added to each tube and incubated for 15 minutes at room 
temperature with gentle agitation. The resin was then centrifuged as previously described, the 
supernatant then removed, and washed with dH2O three more times. 
 
Solutions for Denaturing Discontinuous Electrophoresis 
Monomer solution  
30 g of acrylamide, 0.8 g of N, N’ – methylene bisacylamide was dissolved in dH2O to a final 
volume of 100 ml. the solution was stored at 4˚C in the dark until use.  
4 x running gel buffer (pH 8.8) 
91 g of Tris/HCl was dissolved in dH2O to a final volume of 500 ml. The pH was adjusted to 8.8 
with HCl and stored at 4˚C in the dark until use. 
4 x stacking gel buffer (pH 6.8) 
6.05 g of Tris/HCl was dissolved in dH2O to a final volume of 100 ml. The pH was adjusted to 8.8 
with HCl and stored at 4˚C in the dark until use. 
10 % Sodium Dodecyl Sulphate (SDS) 
10 g of SDS was dissolved in dH2O to a final volume of 100 ml. the solution was stored at room 
temperature until use.  
10 % ammonium persulphate (APS) 
0.1 g of APS was dissolved in dH2O to a final volume of 1 ml. APS was made fresh as needed.  
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Preparation of SDS-PAGE gels 
12.5 % running gel solution (2 gels) 
12.5 ml of monomer solution, 7.5 ml 4 x running buffer, 0.3 ml 10 % SDS and 9.6 ml dH2O were 
mixed, before casting the gels 150 µl of APS and 10 µl tetramethylethylenediamine (TEMED) 
(Sigma-Aldrich; Steinheim, Germany) were added to the solution.  
Stacking gel solution (2 gels)  
 For a gel thickness of 0.75 mm: 1.33 ml of monomer solution, 2.5 ml 4 x stacking buffer, 0.1 ml 
10 % SDS and 6 ml dH2O were mixed, before casting the gels 50 µl of APS and 5 µl of TEMED were 
added to the solution.  
Reducing Sample buffer (2 X)  
2.5 ml 4 x stacking buffer, 4 ml 10 % SDS, 2 ml glycerol, 2 mg bromophenol blue (Saarchem; Merck 
chemicals, Wadeville, SA) and 0.2 ml β-mercaptaethanol were mixed with dH2O to a final volume 
of 10 ml. aliquots of 1 ml were stored at -20˚C until use.  
10 X Tank Buffer  
30.28 g of Tris/HCl, 144.13 g glycine and 10 g SDS were mixed with dH2O to a final volume of 1 
liter. The solution was stored at room temperature until use.  
Casting of SDS-PAGE gels 
Denaturing PAGE gels were cast using a BioRad gel casting system (BioRad; Hercules, CA). The 
casting chamber was assembled and sealed, running gel solution was added to each chamber 
and a layer of isopropanol added to seal and level out the gels. Once polymerized, the 
isopropanol was removed and the stacking gel solution added. The gels were allowed to 
polymerize before being sealed in an airtight bag and stored at 4˚C for up to 2 weeks or until use.  
Electrophoresis procedure 
Gels were resolved under denaturing conditions using the BioRad Gel System (BioRad; Hercules, 
CA) submerged in 1 x Tank buffer, allowing for even heat conduction. All protein samples and 
comtrols were treated with 2 x reducing sample buffer or non-reducing buffer. The protein and 
sample buffer mix was incubated at ~80˚C for 5 minutes, to allow for denaturation of the protein, 
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before being loaded into the wells of the gels. Gesl were run at 10 mA per gel till the samples 
were stacked and at 25 mA per gel to resolve the samples.  
Staining procedures 
Coomassie staining solution  
0.25 g of Coomassie® Brilliant Blue R250 (Sigma-Aldrich; Steinheim, Germany) was dissolved in 
500 ml of methanol, 100 ml acetic acid and 400 ml dH2O. The solution was stored at room 
temperature until use.  
De-staining solution  
400 ml methanol, 70 ml acetic acid and 530 ml dH2O were mixed and stored at room temperature 
until use.  
Protocol for de-staining procedures 
SDS-PAGE gels were stained with Coomassie® Brilliant Blue R-250 solution overnight at room 
temperature with gentle agitation. The gels were then de-stained overnight with de-staining 
solution at room temperature overnight with gentle agitation. Protein bands were visualized 
under white light using a Universal Gel Doc hood (BioRad; Hercules, CA) and images were 
captured using the Quantity One Version Software Program.  
Western blotting solutions and procedure 
Transfer buffer  
200 ml methanol, 100 ml 10 x Tank buffer and 700 ml dH2O were mixed and stored at room 
temperature until use.  
10 x Tris-Buffered Saline (TBS) 
160 g NaCl, 4 g KCl and 60 g Tris/HCl were dissolved in dH2O to a final volume of 2 liters. HCl was 
used to adjust the pH of the solution. The solution was autoclaved and stored at room 
temperature until use.  
T-TBS 
Just before use, 10 x TBS was diluted 1:10 with dH2O and Tween 20® (Sigma-Aldrich; Steinheim, 
Germany) was added to a final concentration of 0.1 % (v/v).  
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Blocking buffer (5 %) 
2.5 g fat free casein milk powder solution in 50 ml T-TBS.  
Western blotting Procedures 
SDS-PAGE gels and nitrocellulose membranes were equilibrated in Transfer buffer and placed on 
the Trans-Blot apparatus. Transfer conditions were set at 20 volts and the between 40 – 180 mA 
(depending on the amount of gels being transferred) for 30 minutes. Following protein transfer, 
the nitrocellulose membrane was blocked in blocking buffer for 1 hour with gentle agitation or 
overnight at 4˚C. The blocking buffer was then removed and the membrane probed with either 
a HRP-conjugated his-probe or HRP-conjugated anti-kappa light chain specific antibody for 1 hour 
at room temperature. The nitrocellulose membrane was washed 3 times, for 5 minutes each, 
with T-TBS on a shaker to remove any unbound antibody. Protein detection was performed by 
standard chemiluminescence methods. Protein bands were using a Universal Gel Doc hood 
(BioRad; Hercules, CA) and images were captured using the Quantity One Version Software 
Program. 
Standard chemiluminescence Methods  
Equal volumes of Stable Peroxide solution and Luminol/Enhancer Solution from the SuperSignal® 
West Pico Chemiluminescent Substrate Kit (Peirce; Rockford, IL, USA) were mixed and added to 
the membrane for 5 minutes at room temperature.   
BCA Assay (Thermo Fisher Scientific; Massachusetts, USA) 
Concentration determination was achieved by means of the Bradford assay making use of the 
BCA assay kit. The experiment was carried out according to the manufacturer’s instructions.  
Bovine Serum Albumin standards were run alongside each sample being quantified. 
Concentrations of the standards ranged from 2000 – 0 g/ml. Samples of 25l of the standards 
and protein of interest were aliquoted in duplicate. A volume of 200 l of working reagent was 
added to each well and allowed to incubate at 56 °C for 30 minutes. Absorbance readings at 570 
nm were determined spectrophotometrically and the concentrations calculated using the LX-560 
microplate software.  
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Appendix 2: Nucleotide sequence of recombinant Ibalizumab Fab 
Fragment and pET15b Expression vector 





ompA                                                                                                                  Ibalizumab Light chain 
GCCATTGCAGTTGCACTGGCAGGTTTTGCAACCGTTGCACAGGCAGATATTGTTATGACC 
61 ---------+---------+---------+---------+---------+---------+ 



























































































































Sequencing result of sub-cloned Ibalizumab Fab fragment construct 
The sequence alignment was completed using the NCBI alignment tool (blast.ncbi.nlm.nih.gov/BLAST.cgi). Expression plasmids were sequenced 
and aligned to the parent insert strand.  Sequence similarity of 100 % was achieved (bottom right hand corner). 
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Western blot detection of histidine tagged IBLZFab and 2dCD4. 
Despite the presence of a his-tag at the N terminal domain of the Fab fragment, detection with an anti 
his-probe was unsuccessful. A 2dCD4 his-tagged protein was run in conjunction with IBLZFab to confirm the 
functionality of the probe. The image shows detection of the 2dCD4 but not the Fab fragment.  
































SDS-PAGE analysis of IBLZFab expression and purification: 
IBLZFab was expressed in BL21 StarTM (DE3) E. coli cells and protein over expression was induced by cooling the incubation temperature to 30˚C for 
overnight expression. Samples were resolved on a 12.5 % SDS-PAGE gel and stained with Coomassie R-250 stain overnight. (A) SDS-PAGE analysis 
under reducing conditions. Reduction of samples leads to the formation of individual chains visible at ~25 kDa. The band around 25 kDa is slightly 
more pronounced in the periplasmic fraction of IBLZFab than the periplasmic fraction of E. coli transformed with empty vector. (B) SDS-PAGE 
analysis under non-reducing conditions. The absence of reducing agent keeps the disulfide bond in the Fab fragment intact. The assembled IBLZFab 
is therefore expected to be approximately 50 kDa and the unassembled chains should be visible at ~25 kDa. Due to low expression, the Fab 
fragment is not distinguishable on a coomassie gel stain. It can be seen from the gels that there is no difference between the banding patterns of 
IBLZFab-pET15b and E. coli transformed with empty pET15b vector. The similarities between the banding patterns could also be due to the 






























































































































































































































Gel filtration LMW Calibration Standards separated on a Sephadex G-75 column  
In order to determine the elution volume and size of the Ibalizumab Fab fragments and fractions of interest, a gel filtration LMW calibration kit 
was separated on the column used. The elution of the Fab fragment occurred between the Conalbumin and Ovalbumin proteins, predicting a size 
of ~50 kDa. The unassembled chains which are approximately 25 kDa eluted within the Carbonic anhydrous range. 
Blue Dextran  
(2000 000 Mr) 
(45.45 ml) 
Conalbumin 
(75 000 Mr) 
(53.14 ml) 
Ovalbumin 
(43 000 Mr) 
(58.88 ml) 
Carbonic anhydrase 
(29 000 Mr) 
(67.55 ml) 
Ribonuclease A 
(13 700 Mr) 
(79.24 ml) Aprotinin 
(6 500 Mr) 
(94.36 ml) 
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